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SUMMARY
This thesis has investigated several aspects of the 
clinical pharmacology of calcium antagonists in man.
The first study in normal volunteers was designed to 
compare the acute pharmacodynamics and pharmacokinetics of a 
new dihydropyridine analogue, nisoldipine, with those of the 
established drug, nifedipine. The results with both drugs 
showed only minor changes in blood pressure and heart rate, 
both drugs had similar terminal elimination half-lifes and 
there were no major adverse effects.
The antihypertensive potential of nisoldipine was, 
therefore, next assessed in a group of patients with 
essential hypertension following both single and multiple 
dosing. The efficacy of the drug was demonstrated after 
acute dosing and was maintained during a one month period 
with nisoldipine as monotherapy.
For many antihypertensive drugs it has proved difficult 
to describe correlations between plasma concentration and 
therapeutic effect and accordingly this was one of the 
specific aims of a subsequent study of the acute and chronic 
effects of the calcium antagonist verapamil in a further 
group of hypertensive patients. To investigate this 
relationship in detail in individual patients concentration 
effect analysis was applied and similar relationships 
between the fall in blood pressure and the plasma 
concentration of verapamil were found after both acute and
1 3
chronic treatment.
Verapamil and nisoldipine were then used in a 
comparative study to investigate the inter-relationship 
between alpha adrenergic receptors and calcium channels.
The effects of each drug on the pressor responses to 
adrenergic and non adrenergic vasoconstriction were assessed 
in a group of normotensive subjects. Intravenous 
incremental infusions of phenylephrine and alpha­
methylnoradrenaline were used to measure the effects on 
peripheral vascular responsiveness, mediated via alpha^ and 
alpha2 adrenoceptors respectively, and angiotensin II was 
similarly used to assess non adrenergic responsiveness. 
Despite the theoretical differences in the relative 
peripheral vascular actions of these two drugs a comparable 
attenuation of all pressor responses was observed after both 
acute and repeated administration. Additionally, there was 
no evidence from this study in man to substantiate the 
finding in some animal experiments that calcium antagonists 
preferentially antagonised responses mediated via alpha2 
adrenoceptors.
The inter-relationship between alpha adrenoceptors and 
calcium channels was also assessed in two further studies. 
With both verapamil and nisoldipine, during 4 days oral 
dosing, there was significant inhibition of platelet 
aggregation. This effect, however, was only in part due to 
an inhibition of alpha2 adrenoceptor mediated aggregation. 
The combined effects of calcium channel blockade and alpha
14
adrenoceptor antagonism were then assessed in a study with 
verapamil and prazosin.
The therapeutic potential of this combination was 
investigated in normotensive subjects to evaluate the 
possible dynamic and kinetic interactions between the two 
drugs. The combination showed an earlier, longer and 
greater hypotensive effect than either drug alone. In part 
this increased effect was due to changes in prazosin 
pharmacokinetics with increases in peak concentration and 
AUC indicating an enhancement of prazosin bioavailability.
Changes in liver blood flow, as assessed- by indocyanine 
green clearance, were thought to have a role in the 
interaction between verapamil and prazosin. Both verapamil 
and nisoldipine were shown to cause acute increases in 
apparent liver blood flow, in normotensive subjects.
Similar changes in renal function were observed. With 
verapamil there were transitory increases in effective renal 
plasma flow whereas nisoldipine significantly increased 
glomerular filtration rate and urinary sodium excretion in 
addition to effective renal plasma flow. The changes 
returned towards placebo values following repeated 
administration,
In the final part of the thesis the effects of calcium 
antagonists on the release of various hormones were studied. 
Nicardipine, following intravenous infusion and oral 
administration in a group of normotensive subjects, 
attenuated the pressor response produced by exogenous
15
angiotensin II but did not inhibit significantly the 
secretion of aldosterone. In a clinical study in 
hypertensive patients, nifedipine did not show significant 
changes in insulin secretion and glucose tolerance in 
response to an intravenous load. Thus, although there is 
experimental evidence for the central role of calcium ions 
on hormone release, these studies failed to demonstrate a 
clinically significant effect attributable to calcium 
antagonist drugs.
In conclusion the results of these studies indicate 
that the antihypertensive effects of calcium antagonist 
drugs result primarily from their activity as peripheral 
vasodilators. This effect includes an action on adrenergic 
mediated vasoconstriction but there was no evidence of an 
additional antihypertensive component related to 
interference with aldosterone release. The relaxant effect 
on smooth muscle was not confined to the peripheral 
vasculature but also caused transitory alterations of renal 
and liver blood flow. These changes, particularly if they 
directly influence drug clearance, may be important for the 
interactions with co-administered drugs. More research is 
still required to define the clinical pharmacology of 
calcium antagonists and their role in the treatment of 
hypertension.
16
CHAPTER 1
INTRODUCTION
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1.1. HISTORICAL REVIEW
Dan Shen is the name of a traditional Chinese remedy 
used for the treatment of coronary disorders.
It is derived from the roots of "Salvia Miltiorrhiza 
Bunge" and the alcoholic extract, "tanshinone II A 
sulphonate", which is the active principal, has been shown 
to have calcium entry blocking properties. These are 
likely to be responsible for its clinical efficacy (Patmore 
and Whiting, 1982).
In the early 1960s the first calcium antagonist, 
verapamil, was introduced into clinical practice in Germany 
as an antianginal agent but originally it was classified as 
a beta adrenoceptor blocker (Melville and Benfey, 1965). 
Further research showed that verapamil also possessed local 
anaesthetic properties and important antiarrhythmic activity 
(Melville et al, 1964; Schmid and Hannah 1967; Garvey,
1969).
In 1969 Fleckenstein classified a heterogenous group of 
drugs and called them "calcium antagonists" to indicate 
their common property of inhibition of the influx of calcium 
into cardiac and vascular smooth muscle cells (Fleckenstein et 
al, 1969). The mechanism of action of verapamil was thus 
elucidated (Fleckenstein et al, 1972; Fleckenstein, 1977) 
and it represented the prototype of a class of 
antiarrhythmic agents (Singh et al, 1972) different from 
beta adrenoceptor blockers and quinidine-1ike drugs. In 
the 1970s verapamil began to receive consideration also in
18
the United States (Singh et al, 1978).
The other landmark of the calcium antagonist story was 
the synthesis of nifedipine, a dihydropyridine derivative, 
in 1971. This substance was first used in Germany and 
Japan for treatment of angina. Since then the concept of 
calcium antagonism has become more widely accepted and 
calcium antagonists have become useful therapeutic agents in 
the treatment of angina pectoris and cardiac arrhythmias 
(Opie, 1980; MacLean and Feely, 1983).
It was further realised that the vasodilator properties 
of these substances were not specific for the coronary 
artery and that they have powerful peripheral arterial 
vasodilator and afterload reducing properties (Wartlier et 
al, 1981; Kahan et al, 1981; Aoki et al, 1982a). Over 
the last few years several experimental and clinical studies 
have focused attention on the value of drugs of this class 
in the treatment of arterial hypertension. By decreasing 
the entry of calcium ions into vascular smooth muscle cells, 
calcium antagonists effectively decrease the strength of 
contraction causing a vasodilation. As most hypertensive 
patients show increased peripheral vascular resistance, the 
use of calcium antagonists as a therapeutic approach to high 
blood pressure seemed most appropriate, and early results 
were very encouraging (Guazzi et al, 1977; Bartorelli et 
al, 1978). It is noteworthy that since 1969, research 
undertaken in Germany and elsewhere had shown the efficacy 
of the calcium antagonist verapamil in the treatment of
19
hypertensive crisis (Brittinger et al, 1969; Bender, 1970). 
More clinical experience has demonstrated that calcium 
antagonists are effective not only in severe, but also in 
mild to moderate hypertension, giving a blood pressure 
reduction both at rest and during exercise (Midtbo et al, 
1982; Klein et al, 1983; Murphy et al, 1983). Nifedipine 
and verapamil are the most widely used drugs of this class 
in the treatment of hypertension and have been joined by 
diltiazem. Recently other dihydropyridines including 
nitrendipine and nicardipine have been actively tested.
There is now real prospect of development of newer compounds 
with greater selectivity of action but their role in the 
treatment of hypertension remains to be established.
Further therapeutic possibilities in the control of a 
variety of cardiocirculatory disorders have been proposed. 
For example, the reported efficacy of nimodipine, a 
nifedipine analogue, in the treatment of cerebral vasospasm 
associated with subarachnoid haemorrhage (Allen et al, 1983) 
and the haemodynamic improvement following diltiazem in 
patients with pulmonary hypertension (Crevey et al, 1982).
1.2. CLINICAL PHARMACOLOGY OF CALCIUM ANTAGONISTS
The organic substances used as calcium antagonist 
drugs can be divided into several distinct groups (Figure 
1.1a, b and c).
1) Papaverine derivatives : such as verapamil, 
gallopamil, tiapamil
20
D I H Y D R O F Y R T D I N E  D E R I V A T I V E S
nifedipine
CCOCM
Fig.1.1.a
Structural formulae of 
calcium antagonist 
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• HCI nicardipine HCl
P A P A V E R I N E  D E R I V A T I V E S
Cfl,Q
CH)0'
CH ÇH.
C-Chj—CH2—CHj—N—Ch',—Cm
C5N
üCiij
ûCHi
Fig.1.1 .b 
Structural formulae 
verapamil
Crt
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Ch
CM-.
CHjO
‘ÛCH4
gallopamil
“lO^!
tiapamil
PIPERAZINE DERIVATIVES
v_y
F
lidoflazine
ai-N N-Cllj-C y ,
cinnarizine
y \ y
C H - N  N-CHj-C" w >-0
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flunarizine
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OTHER!
.c
Structural fomulae
C H — C H 2 — C H j — N H — C H — C H j preny lamine
CH,
.1CH—CH,—CHj—NH—CH-^ ) fendiline
^  A  ■ 1"'CH—CH,—CH—NH—C—CH]Q/ "■ terodiline
perhexiline
BENZOTHIAZEPINE DERIVATIVE
OMe
OCOMe
CH2CH2NMB2
diltiazem
23
2) Dihvdropvridine derivatives : felodipine 
nicardipine, nifedipine, niludipine, 
nimodipine, nisoldipine,
3) Piperazine derivatives : cinnarizine, flunarizine, 
lidoflazine
4) Benzothiazeoine dérivâtes : diltiazem
5) Others: prenylamine, fendiline, terodiline, 
perhexiline.
The action common to all groups is inhibition of the 
inward movement of Ca"*"^  through the cell membrane of heart 
muscle and vascular smooth muscle. There are, however, 
important cellular differences to be considered. In the 
myocardial cell depolarisation is initiated by a rapid 
influx of sodium ions via the fast inward channel. When 
the transmembrane potential has fallen a second inward 
current develops. It is mainly due to Ca'*"*' ions and it 
determines the plateau phase of the cardiac potential.
This slow influx of Ca"*"^  is believed to pass through 
channels anatomically different from those of the fast 
current (Triggle and Swamy, 1983). A further mechanism of 
calcium entry involves Na’^’/Ca'*’ exchange (Blaustein, 1977). 
All these events lead to an increase of intracellular Ca"*"*" 
which stimulates release of more Ca**"^  from intracellular 
sites in the sarcoplasmic reticulum. The high 
intracellular Ca"*"*" concentration activates a cascade of 
events to allow the interaction between actin and myosin and 
the shortening of sarcomere (Braunwald, 1982).
24
In the smooth muscle cell contraction is initiated by 
the activation of the slow channels (Zelis and Flaim, 1981), 
Two distinct types of calcium channels have been postulated: 
a potential dependent calcium channel and a receptor 
operated channel (Figure 1.2.). The influx of Ca++ through 
the latter can also release Ca++ from intracellular stores. 
Intracellular Ca++ links to calmodulin, a calcium modulating 
protein, which activates a myosin light-chain kinase 
(Tomlison et al, 1984). The sequence of events will lead 
to the interaction between actin and myosin to produce 
contraction. A connection between alpha adrenergic 
receptors and calcium channels has been recently 
established. In vascular smooth muscle, alpha^ adrenergic 
stimulation releases Ca++ from an intracellular source 
resulting in an early rapid phase of contraction followed by 
the late slow phase related to the influx of Ca++ across the 
membrane (Deth and Van Breemen, 1974). Alpha2 
adrenoceptors also appear to modulate other calcium channels 
(Van Zwieten and Timmermans, 1983) (Figure 1.3.).
From a therapeutic point of view the most interesting 
drugs are verapamil and nifedipine. In vitro experiments 
have shown that the two drugs depress electrical 
excitability, slow atrioventricular conduction and are 
negative inotropic agents. On vascular smooth muscle they 
act as a vasodilator but the relative potency of verapamil 
is less than that of the dihydropyridine derivatives. Some 
new agents have shown greater vasodilator effects on
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coronary arteries and peripheral vessels. In clinical 
practice, at therapeutic doses they do not depress heart 
contractility and are particularly suitable for the 
treatment of hypertension (Table 1,1.),
Nifedipine is well absorbed after oral or buccal 
administration. An intravenous formulation has not been 
widely available because of poor solubility and 
photolability. Peak plasma concentrations of drug occur 
one or two hours after oral dosing. Nifedipine is 
extensively protein bound in plasma and is metabolised to 
yield lactone and "free acid" pyridine derivatives (Waller 
et al, 1984). The elimination half life of nifedipine has 
been reported as between two and five hours. It has been 
measured by GLC electron capture methods although some of 
these methods have not distinguished the parent drug from 
the metabolites. A study on the antihypertensive effects 
of nifedipine revealed very wide interpatient variation in 
plasma levels relative to oral dosage. However, if 
individual correlations are examined, instead of groups, 
significant correlation between plasma nifedipine levels and 
the magnitude of the individual hypotensive response has 
been shown by several authors (Lederballe Pedersen et al, 
1980a; Aoki et al, 1982b; Pasanisi and Reid, 1983). The 
side effects caused by nifedipine and most dihydropyridine 
derivatives are facial flushing, headache, early in 
treatment, and ankle oedema with more prolonged therapy 
(Kiowski et al, 1983a; Brennan et al, 1983).
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table 1^1^
RELATIVE PHARMACODYNAMIC EFFECTS OF CALCIUM ANTAGONISTS IN MAN
NIFEDIPINE VERAPAMIL
Coronary arterial dilatation ++ ++
Peripheral arterial dilatation +++ ++
Negative inotropism + ++
Hypotens ion ++ +
Reflex beta-adrenerg ic activity ++ +
AV nodal conduction disturbance 0 +++
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TABLE 1 . 2 .
PHARMACOKINETICS QF CALCIUM ANTAGONISTS
NIFEDIPINE VERAPAMIL
Oral absorption > 90% > 90%
Bioavailability 30-60% 10-20%
Onset of action (oral) < 20 rain < 30 rain
Protein binding > 90% > 90%
Elimination half-life (single dose) 2-6 h 3-7 h
Route of elimination Hepatic Hepatic
Active metabolite No Yes
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More pharmacokinetic information is available for 
verapamil (Table 1,2.). It is widely available for both 
oral and intravenous administration. Verapamil is well 
absorbed after oral administration but undergoes extensive 
first pass metabolism. It is approximately 90% plasma 
protein bound (McAllister and Kirsten, 1980, 1982). A 
large number of metabolites have been identified using HPLC 
assay but only its N-demethylated metabolite, norverapamil 
appears to exert significant haemodynamic effects. Non 
linear pharmacokinetics appear to apply to the orally 
administered drug. A tendency for accumulation of 
verapamil has been shown during chronic dosing with a 
significant prolongation of the drug's elimination half 
life. There was also evidence for accumulation of 
norverapamil. This effect has been claimed to be due to 
limited capacity for hepatic metabolism of the drug. The 
clearance of the drug also appears to depend on hepatic 
blood flow and is markedly impaired in patients with liver 
disease (Eichelbaum et al, 1981; Semplicini et al, 1982; 
Weiner et al, 1984).
A wide range of side effects of the various slow 
channel blocking drugs have been described. After long 
term oral administration verapamil may cause constipation. 
Other side effects are gastric irritation, vertigo, 
agitation and headache. Overdose of verapamil may lead to 
atrioventricular dissociation and severe hypotension has 
occurred. The former is more likely if a beta blocker has
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been given concurrently.
1.3. CALCIUM ANTAGONISTS IN HYPERTENSION
It is generally agreed that an increase in cytosolic 
calcium concentration represents the signal that initiates 
the contractile process in vascular smooth muscle. There 
is also experimental evidence that calcium handling by 
smooth muscle cells is abnormal in most forms of 
hypertension (Wei et al, 1976; Zsoter et al, 1977; Daniel 
and Kwan, 1981). The development, therefore, of drugs that 
interfere with the entry of Ca++ ions into cells has provided 
the clinicians with important new therapeutic agents for use 
in the treatment of systemic arterial hypertension.
The available clinical data suggest a potentially 
important role for the calcium channel blockers in the future. 
Their clinical utility has not, however, been fully 
established, particularly with respect to adverse effects 
during long term therapy. To date studies of the calcium 
antagonists have mainly examined the acute and chronic 
(months) treatment of hypertension in uncontrolled studies. 
Preliminary information is available regarding the combination 
of calcium antagonists with other antihypertensive drugs, but 
such combinations need further evaluation.
Several reports demonstrating the efficacy of 
nifedipine in patients with hypertensive emergencies have 
been published (Ueda et al, 1979; Guazzi et al, 1977).
After sublingual administration of nifedipine mean arterial
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pressure decreased significantly. The onset of action was 
seen within minutes and the main side effect was facial 
flushing (Beer et al, 1981; Ueda et al, 1979)'. Acute 
reduction in blood pressure was often (Aoki et al, 1978; 
Lederballe Pedersen et al, 1980a) but not always (Corea et 
al, 1980) accompanied by an increase in heart rate, probably 
due to baroreceptor mediated reflex stimulation.
The effect is dose related (Lederballe Pedersen et al, 
1980b) and the higher the blood pressure before treatment, 
the greater the fall in pressure that follows the drug 
(Ekelund et al, 1979; Guazzi et al, 1980). -Young 
normotensive subjects do not usually drop their blood 
pressure in response to nifedipine although transient 
tachycardia is seen.
There are fewer studies concerning the usefulness of 
calcium antagonists as single agents in chronic hypertension 
(Lederballe Pedersen and Mikkelsen 1978; Buhler, 1983).
The efficacy of nifedipine appears to be dose-related, 
with a moderate decrease in arterial pressure following 
doses of 10 mg of the capsule formulation (Ueda et al, 1979; 
Levenson et al, 1983) and more dramatic reductions in 
pressure occurring with 30 mg doses (Aoki et al, 1976).
The duration of antihypertensive action is also dose-related 
(Lederballe Pedersen and Mikkelsen, 1978). During chronic 
oral therapy, nifedipine 10 mg has an antihypertensive 
effect which lasts 8-12 hours. Administration every 6 
hours significantly reduces blood pressure throughout the
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day. This drug also causes an acute increase in urinary 
output and sodium excretion (Klutsch et al, 1972) and raises 
plasma renin activity and noradrenaline concentration in the 
short term (Aoki et al, 1978; Corea et al, 1979, 1980). 
However plasma aldosterone does not change (Lederballe et 
al, 1979). Chronic treatment did not result in any 
consistent change in plasma renin activity (Lederballe et 
al, 1979; Corea et al, 1980). These results suggested 
that nifedipine may be useful as a single agent in the 
control of hypertension.
Verapamil has been successfully used intravenously 
during acute hypertensive crises (Bender, 1980). As for 
nifedipine, oral administration of verapamil has little or 
no effect on blood pressure of normotensive subjects but 
lowered blood pressure of hypertensives with no significant 
change in heart rate and plasma renin activity (Leonetti et 
al, 1980; Corea et al, 1981), Verapamil is also effective
in the long term treatment of mild to moderate essential 
hypertension in daily doses ranging from 240 to 720 mg 
(Leonetti et al, 1980; Midtbo and Hals, 1980; Anavekar et 
al, 1981; Corea et al, 1981). Conflicting results,
however, have been reported by other groups. Its 
hypotensive effect was not sustained in one trial of 320-640 
mg daily over a seven week period (Lederballe, 1978). In a 
later study, using a continuous intra-arterial pressure 
monitoring, before and after six weeks of oral verapamil 
treatment (120-160 mg b.d.) the drug was demonstrated to
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produce a significant reduction in blood pressure (Gould et 
al, 1982). The wide individual variation in the response 
to verapamil has been explained on the basis of high first 
pass metabolism (Midtbo, 1980).
When verapamil and nifedipine have been directly 
compared a similar antihypertensive activity has been 
demonstrated (Gould et al, 1982; Leonetti et al, 1982;
Muiesan et al, 1982).
There is clearly a need for further controlled studies 
of calcium antagonists alone and in combination with other 
agents in patients with hypertension.
1.4. SCOPE OF THE THESIS
Calcium ions have a central role in a variety of 
processes particularly in the contraction of muscle cells in 
the heart and the peripheral vasculature. This forms the 
theoretical basis for the potential usefulness of substances 
antagonising calcium influx into the cell in a wide range of 
cardiovascular disorders. With respect to the clinical use 
of calcium antagonists, the review of the literature has 
revealed a lack of detailed information on aspects of the 
pharmacokinetics and the pharmacodynamics, particularly of 
the dihydropyridine derivatives.
In this thesis detailed studies have been undertaken with 
both verapamil and nifedipine, and additionally with the 
analogues nisoldipine and nicardipine. These studies have 
addressed several themes. For example the clinical
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haemodynamic effects of nifedipine have been compared with the 
new dihydropyridine nisoldipine in normal volunteers and 
subsequently the new drug was tested in hypertensive patients. 
An evaluation of the relationship between plasma 
concentration of verapamil and blood pressure reduction was 
also undertaken in hypertensives. The mechanisms 
underlying the peripheral vascular effects of calcium 
antagonists have been assessed by investigating the 
relationship between calcium channels and alpha 
adrenoceptors in the regulation of vascular tone. A
study of the pressor responses to different agonists in man 
and an evaluation of platelet aggregation during 
administration of calcium antagonist drugs were undertaken. 
Detailed studies of the interaction between a calcium 
antagonist and a selective alpha^ adrenoceptor blocker are 
also described. Further pharmacodynamic and 
pharmacokinetic issues concerning the effects of acute and 
prolonged dosing with calcium antagonist drugs on renal and 
hepatic function have been studied. This has possible 
implications for the kinetics during long term 
administration and differences in the acute and chronic 
effect. Finally, the effects of nicardipine and nifedipine 
on hormone secretion has been evaluated in normotensive and 
hypertensive subjects.
This thesis represents an attempt to clarify some aspects 
of the clinical pharmacology of calcium antagonist drugs.
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2.1. General Procedure
All the protocols of the clinical studies 
described in this thesis were approved by the Research 
and Ethical Committee of the Northern District of the 
Greater Glasgow Health Board. All subjects gave their 
informed written witnessed consent prior to 
participation. Studies were performed in a quiet room 
at constant temperature in the Clinical Pharmacology 
Research Unit of the Department of Materia Medica. A 
clinical examination, full biochemical, haematological 
and ECG screening was undertaken before the study and 
repeated at the end.
Subjects attended the CPRU at approximately 8.30 in the 
morning of the study having avoided all drugs for at least 
one week before each study day and abstained from alcohol, 
caffeine-containing beverages and cigarette smoking from
22.00 hours the day before the study. A light breakfast of 
orange juice and toast was allowed between 7 and 7.30 on the 
morning of the study unless otherwise specified. A blood 
pressure cuff was applied and an indwelling cannula 
(Venflon, Viggo) inserted into an antecubital vein for blood 
sampling and for the infusion of pressor substances.
Cannulae were kept patent by intermittent flushing with 
heparinised saline solution. During the infusions standard 
ECG leads were applied and the ECG displayed on a Grass 
Polygraph (Grass, Polygraph).
Following a period of 30 minutes quiet recumbency in
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bed after insertion of the cannula, baseline readings of 
blood pressure and heart rate by semiautomatic recorder 
(Sentron, Bard Biomedical) were taken and blood samples 
collected for baseline (time 0) drug or hormone levels. 
Thereafter subjects received their treatments. Subsequent 
blood pressure readings were taken at frequent intervals, in 
the supine position after at least 10 minutes recumbancy and 
on standing after 2 and 5 minutes, or until the systolic 
pressure fell to 80 mmHg or less, or until orthostatic 
symptoms were experienced by the subjects. Blood samples 
were also taken throughout the day at corresponding times.
Observations were typically made over a period of 10 
hours and side effects were carefully recorded.
Full resuscitation equipment was available at all 
times.
2,2. Determination of plasma noradrenaline 
concentration
Plasma noradrenaline concentrations were estimated 
by the radioenzymatic assay of Henry et al (1975).
Venous blood was withdrawn from an indwelling cannula 
inserted in the forearm and collected into lithium 
heparin tubes. Plasma was separated by centrifugation 
at 4°C for 15 minutes at 3000 rpm and stored at -70^C 
until assay.
The method utilizes the conversion of norepinephrine 
(NE) to tritiated epinephrine (E) by partially purified
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bovine adrenal phenylethanolamine-M-methyl-transferase 
(PNMT) and tritiated S-adenosyl-methionine (SAME),
The first stage of the assay is the concentration 
phase. To 1 ml of plasma was added 100 jxl of sodium 
metabisulphite, 5 mg 100 ul noradrenaline as internal 
standard, 50 mg of alumina, 0.5 ml of tris buffer (1.0 M 
tris HCl containing 2 g/100 ml EDTA; pH 8.6, The mixture 
was agitated and washed with water several times, the 
supernatant removed and 100 /il of it added to 100 ul of 0.01 
M H:C1. The external standard was prepared with 1 ng 
noradrenaline in a volume of 100 ul and 100 ul 0.1 M HCl). 
The blank contained 100 /il of 0.01 M HCl and 100 ul 0.1 HCl.
The reaction mixture was made up dissolving 1 mg DTT 
into 10 ml tris buffer (2,0 M tris HCl containing 5 g/100 ml 
EDTA: pH 8.6) to give a final concentration of 0.1 mg/ml.
To 1.5 ml of the mixture were added 0.1 ml tritiated-S- 
adenosyl methionine (H-SAMe) and 0.4 ml PNMT.
Fifty ul of the mixture were added to each sample 
and incubated for 1 hour at 37°C in an agitated water 
bath. The reaction was terminated by addition of 2 ml 
tris phosphate buffer 2.0 M tris H/Cl containing 0.5 Na 
phosphate + H2O, 5 g/100 ml EDTA: pH 8.6). In the final 
stage 50 mg of alumina were added and after vortexing 
supernatant was removed. One ml 0.1 M perchloric acid, 200 
jul phosphotungstic acid and, 100 jul non tritiated SAMe were 
added.
After vortexing, refrigeration and centrifugation 1 ml
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was taken and added to 1 ml potassium phosphate in a plastic 
tube. Upper organic phase was separated by freezing lower 
aqueous layer in acetone/dry ice. A vial containing 0.4 ml 
permafluor was used for counting in a liquid scintillation 
counter (PACKARD TRICARB). The intra assay coefficient of 
variation was 10% and the interassay coefficient of 
variation was 12-15%.
2.3. Determ ination of plasma renin activity
Plasma renin concentration was measured by incubation 
of plasma with sheep renin substrate (angiotensinogen) at 
37°C by the method of Skinner (1967). Angiotensin I 
generated during the incubation was assayed by 
radioimmunoassay. Venous blood was withdrawn from an 
indwelling cannula inserted in the forearm and collected 
into potassium EDTA tubes. Plasma was separated by 
centrifugation at 4°C for 15 minutes at 3000 rpm and stored 
at -20°C until assay. The first step of the assay 
consisted in the incubation of renin with angiotensinogen to 
generate angiotensin I. Fifty ul of plasma were added to 
50 jxl of fresh buffer inhibition mixture (45 ml phosphate 
buffer pH 7.5 + 1 ml PMSF solution + 2 ml trasylol + 2 ml 8 
OHQ) and to 100 jiil sheep renin substrate (containing 0.1% 
neomycin sulphate). Two sets of samples were taken: one
was incubated for 1.3 hours at 37°C and the other at 4°C for 
the same time. Two hundred ul of tris acetate buffer (tris 
base 0.1 /il/1 + neomycin 0.2% w/v + bovine serum albumin
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0.35% + lysomycine 0.1%) were added to stop the enzymatic 
reaction. Samples were then stored at -20°C. The second 
step of the assay is the radioimmunoassay of generated 
angiotensin I. Ninety /il of renin antibody were taken and 
dilute to 100 ml tris acetate buffer at 4°C. One ampoule of 
l125 angiotensin I (New England Nuclear) was dissolved in 5 
ml tris acetate buffer. This solution was diluted so that 
50 /il gave counts of 10,000-12,000 cpm.
Fifty ul of the 1^25 angiotensin I solution were added 
to 50 /il of the generated angiotensin I samples or standards 
and to 500 fil of the antibody solution for each sample. 
Samples were incubated at 4°C for 18-24 hours. After 
separation of free and bound antigen by charcoal separation 
and followed by centrifugation samples were counted using a 
gamma counter (BERTHOLD LB 2100, MULTI CRYSTAL GAMMA 
COUNTER).
The intra-assay coefficient of variation was 5.5%.
The inter-assay coefficient of variation was 10%.
2.4. Determ ination of Plasma Aldosterone Concentration
Plasma aldosterone concentrations were estimated by 
radioimmunoassay of De Man et al (1980) and using materials 
supplied in kit form by CIS International (St. Quentin, 
France).
Venous blood was withdrawn from an indwelling cannula 
inserted in the forearm and collected into lithium heparin 
tubes. Plasma was separated by centrifugation at 4°C for
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15 minutes at 3000 rpm and stored at -20°C until assay.
The principle of the assay is based on the competition 
between the labelled aldosterone and aldosterone
contained in standards or specimens to be assayed, for a 
fixed and limited number of antibody binding sites. After 
the incubation, the amount of labelled aldosterone bound to 
the antibody is inversely related to the amount of 
unlabelled aldosterone present in the sample. In the 
commercial preparation the anti-aldosterone serum is bound 
to the inner surface of the tube so that separation of free 
and antibody-bound ligand is achieved by decanting, whereas 
a dextran charcoal separation with dissolved antibody is 
described by De Man. The assay of each plasma sample was 
performed in duplicate. The radioactivity of all tubes 
were measured using a gamma counter (BERTHOLD LB 2100, MULTI 
CRYSTAL GAMMA COUNTER).
The intra-assay coefficient of variation was 7.3% and 
the inter-assay coefficient of variation was 10%.
2,5. Determination of Serum Insulin Concentration
Serum insulin concentrations were estimated by 
radioimmunoassay of Zick et al (1982) and using materials 
supplied by kit from Behringweeke AG (Marburg, W. Germany). 
Serum from blood samples was separated after blood 
collection and stored at -20°C. 100 fil standard or serum
and 200 fil distilled water were added to the test tubes for 
the insulin assay. The contents of test tube were dissolved
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and mixed thoroughly on a vortex. Samples were covered and 
incubated for 24 hours at 20°C. 1 ml of polyethylene glycol
solution was added to each test tube to effect the separation 
of antibody-bound and free insulin. The solution was 
homogenised on a mixer before centrifugation of the turbid 
solution for 15 minutes at 1,500 rpm.
The supernatant fluid was drawn off and radioactivity 
of the precipitate of the tube was evaluated for one minute 
in the ^^I-channel of a gamma scintillation counter.
The intra-assay coefficient of variation was 10% and 
the inter-assay coefficient of variation was 15%.
2.6. Determination of Serum C-Peptide Concentration
C-peptide concentrations were estimated by 
radioimmunoassay using material supplied in kit from ByK- 
Mallinckrodt (Dietzenbach, W. Germany), 100 fjtl of C- 
peptide standard or serum were added to test tubes plus 
100 jüH C-peptide solution. 100 fil of C-peptide antiserum
were also added to each test tube and mixed on vortex.
Test tubes were incubated for 24 hours at 20°C, 500 ul
goat-anti-rabbit-gamma globulin solution was added to each 
test tube and mixed on vortex. Test tubes were incubated 
for 30 minutes at 20°C then centrifuged at 2000 rpm for 20 
minutes. Supernatant was removed and remaining activity 
counted with a gamma-counter.
The intra-assay coefficient of variation was 10% and 
the inter-assay coefficient of variation was 15%.
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2.7. Determination of verapamil and norverapamil
The method used is based on the direct high-performance 
liquid chromatographic (HPLC) analysis of an extract of a 
relatively small sample volume, and permits the simultaneous 
measurement of verapamil and norverapamil in the presence of 
the two remaining principal metabolites. The metabolite 
D 517 was used as internal standard (Cole et al, 1981).
The solvent delivery system was a constant-flow 
reciprocating pump (Applied Chromatography Systems, Model 
750/04) and sample injection was performed using a Rheodyne 
Model 7125 syringe-loading valve fitted with a 100 ul sample 
loop. Stainless steel tubing (0.25 mm I.D.) was used to 
connect the outlet port of the valve to the analytical 
column, a stainless steel tube 125 x 5 mm I.D. packed with 
Spherisorb 5 silica (Hichrom. Woodley, Great Britain), which 
was used at ambient temperature (normally 22°C). The 
column effluent was monitored using a Schoeffel Model FS 970 
fluorescence detector, with an excitation wavelength of 203 nm, 
no emission filter and a time constant of 0.5 sec. The 
mobile phase was a solution of potassium bromide (3 mM) and 
perchloric acid (0.37 mM, equivalent to 0.004%, v/v) in 
methanol, and was helium-degassed before use. The flow 
rate was 2.0 ml/min, maintained by a pressure of 
approximately 60 bar.
The chromatography on this system of a methanolic 
solution containing verapamil and the three metabolites 
under study, together with the internal standard, is
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illustrated in Figure 2.1. The retention times, measured 
relative to the internal standard, of verapamil, the 
metabolites under study and some additional compounds are 
given in Table 2.1.
Plasma or serum (100 fil) was pipetted into a small 
(Dreyer) test tube (Poulton, Selfe and Lee, Wickford, Great 
Britain). Internal standard solution (50 /il), sodium 
hydroxide solution (50 jul) and methyl tert,-butyl ether 
(200 fil) were added using Hamilton repeating mechanisms fitted 
with Hamilton gas-tight luer-fitting glass syringes and 
stainless steel needles. The contents of the tube were 
vortex-mixed for 30 sec and centrifuged at 9950 g for 2 min 
in an Eppendorf centrifuge 5412 (Anderman, East Molesey,
Great Britain), Subsequently, a portion (approximately 
110 jul) of the extract was taken and used to fill the sample 
loop of the injection valve.
Duplicate sample analyses were performed, and the mean 
result taken.
The intra-assay and the inter-assay coefficients of 
variation were less than 5% for both verapamil and 
norverapamil. The limit of detection of the assay was 2 
jug/L using a 100 jul sample.
2.8. Determination of Prazosin
The assay was performed according to the method of Yee 
et al, 1979. Whole blood or plasma 0.1 - 1.0 ml, was added 
to an 8 ml capacity culture tube fitted with a PTFE-lined
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Fig. 2.1. Standard HPLC chromatogram.
Simoultaneous determination of verapamil and prazosin.
Tab. 2.1. Characteristics of the peaks.
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screw cap and containing 54 ng of the internal standard 
added to 100 jil of water. Water was added to samples with 
less than 1,0 ml, so that all tubes had an equal volume of 
aqueous phase. The blood was alkalinized with 200 jul of 2 
N sodium hydroxide and extracted immediately with 5 ml 
diethyl ether to prevent the formation of solid aggregates. 
Samples were mixed on a Labquake for 10 min and then 
centrifuged for 10 min. The aqueous phase was frozen by 
placing the tube in an acetone-dry ice bath and the organic 
phase decanted into an 8 ml tube with an elongated cone at 
its base, of approximately 30 jul capacity, containing 20 ^1 
of 0.1 N sulfuric acid. The sample was extracted with a 
Vortex mixer for 1 min, the tubes chilled in the 
refrigerator for 10 min and then centrifuged for 5 min.
All or part of the dilute sulfuric acid, sampled through the 
diethyl ether with a 25 /Al syringe, was injected into the 
high pressure liquid chromatograph.
A Varian model 8500 dual pump gradient elution high 
pressure liquid chromatograph fitted with a varian micro-Pak 
MCH-10 (monomeric C^g bonded) reversed-phase column (25 cm x
2.0 mm I.D.) was used for the analysis. One pump contained 
a 0.01 M solution of pentane sodium sulfate in water 
adjusted to pH 3.4 with glacial acetic acid (solvent A).
The other pump contained the same concentrations of pentane 
sodium sulfate and acetic acid as solvent A in methanol 
(solvent B). Both solvents were filtered before use. An 
isocratic mixture of 49% solvent B and 51% solvent A was
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used with daily minor adjustments in solvent composition (1- 
2%) to maintain optimum baseline separation of prazosin and 
the internal standard. The flow rate of the solvent 
mixture was 40 ml/h, with a column input pressure of 150 atm 
(2300 p,s.i.). The column was insulated with sponge rubber 
in order to minimise baseline noise, A Varian Fluorichrom 
with a deuterium lamp and Baird Atomic 20 nm bandpass 
filters, 253.1 nm for excitation and 390 nm for emission was 
used. A 0.5 jLim porosity stainless-steel frit was placed on 
the efferent side of the detector to maintain the detector 
pressure thereby preventing formation of bubbles. A Varian 
A25 dual pen recorder was employed with one pen set at 1 mV 
full scale deflection and the other varied between 2 mV- 
50 mV depending on the expected concentration of the sample.
A standard chromatogram is shown in Figure 2.2.
The assay was calibrated by adding known amounts of 
prazosin (0.2 ng-50 ng) and internal standard (54ng) to 1 ml 
of whole blood or plasma which was then analysed. The 
peak height ratio (PHR) of prazosin to the internal standard 
was plotted versus the amount of prazosin added. To 
determine the accuracy and precision of each set of unknown 
samples a calibration curve consisting of 0.2, 0.5, 1, 2, 5, 
10, 20 and 50 ng of prazosin was assayed along with the 
unknown samples. The PHR of the standard samples were 
divided by the amount of the prazosin added to derive the 
amount of prazosin in the unknown samples and the 
coefficient of variation provides an estimate of the
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Fig.2.2. HPLC Of prazosin.
(A) chromatogram of extracted vAole blood containing 
5ng of prazosin (peak P,3 min) and 54 ng of internal
standard (I.S.,4.5min)with attenuation at 5 mV full
scale deflection.
(B) and (C) chromatograms of extracted control whole 
blood and plasma,respectively. No peaks are seen 
corresponding to prazosin (P) and internal standard 
(I.S.) ,with attenuation at 2 mV full scale deflection.
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accuracy of the method over the range of standard samples. 
The reproducibility of the method was investigated by 
analysing five replicate samples in whole blood and ten 
replicate samples in plasma of 2 ng and 20 ng concentrations 
of prazosin. The effect of variable sample size was 
studied using 0.2-2.0 ml of whole blood or plasma without 
the addition of water, keeping constant the volume of 
internal standard solution, sodium hydroxide, and diethyl 
ether. The recovery of prazosin was determined by 
comparing the peak heights of extracted known concentrations 
of prazosin injected directly into the chromatograph.
The stability of prazosin in heparinized whole blood 
was investigated by assaying samples after they had been 
frozen at -20° for 6 months, refrigerated for up to 5 days 
or left at room temperature for 1h, 2h, 3h or 5h. The 
internal standard was added at the time of analysis. 
Concentrations in each stored set were calculated from the 
normalized PHR of a freshly prepared calibration curve 
analysed on the same day.
2.9. Determination of Nifedipine
Plasma nifedipine concentrations were determined after 
extraction under basic conditions into toluene and volumes 
of 2 jxl were injected directly into a gas liquid 
chromatograph equipped with an OV-101 column and ^^Ni 
electron capture detector (Hamann and McAllister, 1983).
Nitrendipine was used as internal standard. The limit
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of detection is 1-2 ng/ml. The intra-assay coefficient of 
variation of the method, given a plasma nifedipine 
concentration of 50 pg/1 is 6% and the inter-assay 
coefficient of variation is 7%.
2.10. Determination of Nisoldipine
Nisoldipine plasma levels were assessed by the method 
of Ramsch (unpublished data) using gas liquid chromatography 
with an electron capture detector. The limit of detection 
is 2 jig/1. The assay was performed by Bayer AG, Wuppertal, 
Germany.
2.11. Determination of liver blood flow bv Indocvanine 
green
Indocyanine green (ICG) is a water soluble, 
tricarbocyanine dye with a peak spectral absorption at 800- 
810 nm in plasma or blood. Following intravenous 
injection, ICG is rapidly bound to plasma proteins of which 
albumin is the principal carrier (95%) Indocyanine green 
undergoes no significant extrahepatic or enterohepatic 
circulation and is taken up from the plasma almost 
exclusively by the hepatic parenchymal cells and is secreted 
entirely into the bile. Its rate of elimination in normal 
individuals is highly dependent on hepatic blood flow, 
consequently ICG has been used to estimate liver blood flow 
(Caesar et al, 1961). Subjects were studied in a fasting basal 
state in the supine position. Subjects were weighed and
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the dosage calculated on the basis of 0.5 mg/kg of body 
weight. Fifty mg ICG powder was dissolved with 10 ml 
sterile distilled water giving 5 mg of dye per ml of 
solution. The appropriate amount of dye was injected into 
an indwelling cannula inserted in a forearm vein as rapidly 
as possible as a bolus. Six ml of venous blood were 
collected prior to injecting ICG, for a serum blank and 
standard curve construction, and then further samples were 
collected into lithium heparinised tubes at 3, 6, 9, 12, 15, 
18 and 21 minutes after administration. Samples were 
centrifuged and the plasma was separated and stored at -20°C 
until analyis. Indocyanine green plasma concentrations 
were determined after the precipitation of proteins by the 
addition of 1 ml cold (4°C) acetone to 1 ml plasma. After 
mixing by vortex (x 10 secs) samples were centrifuged at 
1000 rpm for 20 minutes. The absorbance of the supernatant 
was measured at 786 nm with a double beam spectrophotometer 
equipped with a red sensitive photomultiplier as described 
by Svensson et al (1983). Calibration curves were obtained 
in each subject’s plasma on each study day. AUCq^oo was 
estimated by the log trapezoidal rule. VDss was calculated 
by the following equation
VD = DOSE/Co
where Co is the concentration at zero time determined by 
extrapolation. Indocyanine green plasma clearance was
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calculated from dose divided by , and this was
converted to blood clearance by the following equation:
Clg = plasma clearance x 1/1-haematocrit
Haematocrits were estimated in each subject on the morning 
of each study day. A one compartment model has been found 
appropriate to determine ICG clearance (Figure 2.3.).
2.12. Determ ination of Glomerular Filtration Rate and 
Effective renal plasma flow using ^ C r  EDTA 
and 1 PAH 
Glomerular filtration rate (GFR) and effective 
renal plasma flow (ERPF) were determined by evaluation 
of the plasma clearances of ^^Cr EDTA and 1^25 p g i v e n  
by intravenous injection (Harries et al, 1972).
Subjects were studied in a fasting basal state in the 
supine position. A total volume of 5 ml containing 2 M 
Bq of 51cr-EDTA and 1 M Bq of I^^S p^^ was injected into 
a venous cannula inserted in the forearm vein, 1 hour 
after oral administration of either drug or placebo.
A 3 ml blood sample was taken before the injection 
and further 3 ml samples were collected from the other 
arm at 2, 7, 17, 30, 40, 75, 100, 120, 150, 180 minutes 
after injection in plastic heparinised tubes. The 
exact time at which the injection was given and the 
samples were taken was carefully recorded. A pooled
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urine collection 3 hours after the injection was taken 
and the volume was estimated. One ml sample of plasma 
urine and the standard solution were simultaneously 
counted in a gamma counter (LKB-WALLAC). *^*Cr has a 
gamma ray emission of 323 KeV and of 35 KeV.
The clearance of the substances was calculated 
according to the following equation;
% dose excreted in urine over 3 hours
^^^0-3 hours
The AUCQ_2 hours represents the area under the % plasma 
concentration of tracer from time of injection to 3 
hours.
2.13. Analvsis of pressor responses
Pressor substances such as phenylephrine, 
alphamethylnoradrenaline and angiotensin II (Figure
2.4.) are injected intravenously in 0.9% sodium chloride 
solution (total infusion volume 40 to 160 ml) with a 
Braun Perfusor IV continuous infusion pump that has a 
series of predetermined dose rates (Sumner et al, 1982). 
Each infusion dose is maintained for not less than 5 
minutes while recordings are made of blood pressure and 
heart rate by automatic recorder (Sentron, Bard) at 
minute intervals. A steady state response should be 
achieved at each infusion rate, after which the infusion 
rate is increased to the next level. The infusion is 
stopped when an increase of not more than 45 mmHg
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systolic pressure or 30 mmHg diastolic pressure is 
achieved. Heart rate is monitored continuously by EGG, 
Thus the systolic and diastolic blood pressures are 
measured at each infusion dose rate and the response is 
calculated by subtracting the baseline values,
A line or curve is drawn through the set of points 
representing the blood pressure responses at particular 
doses of agonist. The dose of agonist required to raise 
the blood pressure by 20 mmHg (PD20) is obtained by 
interpolation.
In clinical studies, the linear and the lower portion 
of the sigmoid dose-response curve can be obtained,
A satisfactory fit to the curve is obtained by the use 
of a quadratic function of the form:
AX^ + BX +C
where X = log (dose) for the pressor-response curve,
2.14. Statistical Analvsis
Where applicable the results were calculated and 
expressed as mean + standard deviation (S.D.), the standard 
deviation being calculated from the expression:-
...
’ n - 1
- x)2
where x was any of the values measured, x the mean value.
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and n the number of observations.
The significance of the results was calculated by 
Student's t test using the formula:-
t K
where s was an estimate of the combined standard deviation 
of both groups calculated from:-
^ ( x  -
n ^ + n 2 - 2
the degrees of freedom F = n^  + n2 - 2
X^ and X2 were the means of both groups and n^ and n2 the 
number of observations in each group.
The significance of paired sets of data was analysed by 
a paired Student's t test using the formula:-
V T T
where x was the mean of the differences between the paired 
samples and S was calculated from:-
(X -
n - 1
The degrees of freedom F = n-1.
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CHAPTER i
STUDIES ON THE EFFECTS OF CALCIUM ANTAGONIST DRUGS 
IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS
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3.1. INTRODUCTION
Calcium antagonist drugs are now widely used in the 
treatment of ischaemic heart disease and hypertension. The 
dihydropyridine nifedipine has an established place as 
second or third line drug particularly in combination with 
beta blockers (Murphy et al, 1983; Kendall et al, 1984; 
LeJeune et al, 1985). Recent observations suggest that 
calcium antagonists may also be used successfully as 
monotherapy in some groups of patients, particularly in the 
elderly and in those with chronic respiratory disease, 
peripheral vascular disease or other absolute or relative 
contraindications to beta blockers (Buhler et al, 1982). 
Several experimental and clinical reports indicate 
differences between calcium antagonists as far as their 
tissue specificity is concerned (Kahan et al, 1981; Crevey 
et al, 1982; Allen et al, 1983). These findings have 
promoted interest in the development of more selective and 
specific drugs.
The dihydropyridine compound, nisoldipine, is an 
example of such development. Compared to nifedipine it has 
similar effects on the heart but exerts a more potent 
inhibition of vascular contraction in vitro. In dogs 
nisoldipine has been found to decrease total peripheral 
resistance by dilatation of the peripheral arterial system 
(Maxwell et al, 1982). In addition, it appears the 
first calcium antagonist for which an effect on the venous 
system has been demonstrated at therapeutic concentrations.
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The portal vein also seems to be sensitive to nisoldipine 
in vitro (Kadza et al, 1980). Intravenous administration 
of nisoldipine to patients undergoing cardiac 
catheterisation caused an immediate blood pressure fall and 
heart rate increase with a marked reduction of total 
peripheral resistances (Vogt et al, 1980) showing that 
nisoldipine was a rapid and powerful peripheral vasodilator 
with its actions apparently restricted to the peripheral 
vasculature. On account of its relatively modest direct 
effect on cardiac muscle and its relative peripheral 
vascular specificity and potency, nisoldipine has potential 
therapeutic advantages over nifedipine in hypertension.
This study investigates the effects of oral nisoldipine on 
blood pressure, heart rate and circulating hormones in both 
normotensive subjects and patients with essential 
hypertension.
3.2. METHODS
3.2.1. Study of normotensive subiects
A double blind, double dummy, random order comparison, 
using a Latin square design, was made of three single dose 
treatments :
1) Nifedipine 20 mg retard tablet and nisoldipine placebo
2) Nisoldipine 10 mg tablet and nifedipine placebo
3) Nifedipine placebo and nisoldipine placebo.
The study was undertaken in nine healthy male
volunteers, aged 20-29 years (mean age 23.5 ± 3 years; mean
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weight 68.3 ± 6 kg) on three study days at least one week 
apart. Blood pressure and heart rate were measured by 
automatic recorder (Sentron) at intervals up to eight hours 
after dosing. From an indwelling cannula (Venflon) 
inserted in a forearm vein blood for drug level measurement 
was collected at time 0, .5, 1, 1.5, 2, 3, 4, 6 and 8 hours 
after administration.
Samples for plasma noradrenaline, aldosterone and renin 
activity were taken at time 0 and 2, 4 and 8 hours after 
dosing. In view of the potential photolability of the 
dihydropyridines blood samples were wrapped in aluminium 
foil and after centrifugation plasma was separated under a 
sodium lamp. Plasma nifedipine and nisoldipine 
concentrations were measured by GLC with electron capture 
(Hamann and McAllister, 1983).
Plasma drug concentration-time data were most 
appropriately fitted to a one compartment open model. By 
application of the general linear (F ratio) test to a 
hierarchy of pharmacokinetic models this model was deemed 
most appropriate for both drugs.
3.2.2. Study of hypertensive patients
Eight patients, 3 males and 5 females, aged 40-60 years 
(mean age 54.5 ± years; weight 67.4 ± 15 kg) with essential 
hypertension (blood pressure > 150/100 and < 240/125 on two 
occasions one week apart) on no treatment for at least two 
weeks, entered the study. All patients had normal renal
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function and no clinical evidence of secondary hypertension. 
Three patients had been previously treated with beta 
blockers, two with diuretics, two with calcium antagonists 
and one had had no previous treatment. After a two week 
placebo period they were treated with nisoldipine 10 mg 
tablets twice daily as monotherapy. Patients were asked to
avoid taking any other drugs during the study period. 
Patients were studied on three 8-hour study days;
1) after at least two weeks on placebo
2) after the first dose of nisoldipine 10 mg (acute)
3) after four weeks treatment with nisoldipine 10 mg
twice daily (chronic).
In all studies blood pressure and heart rate were 
measured, using an automatic recorder (Sentron) in the 
supine position, after a minimum of 10 minutes rest, and 
after 2 and 5 minutes standing. Readings were taken before 
and 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours after dosing.
Blood samples for plasma noradrenaline aldosterone and renin 
activity were collected at baseline, 2, 4 and 8 hours. Side 
effects were assessed both by spontaneous comment and by 
direct enquiry from a standard list of questions. The 
hypertensive patients attended the outpatient clinic at 
weekly intervals for review of blood pressure and side 
effects for four weeks.
Both protocols were aproved by the Ethical Committee 
and all subjects, volunteers and patients, gave written 
witnessed informed consent for participation in the studies.
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Routine biochemical and haematological measurements 
were undertaken before commencing the studies and repeated 
at the end. A 12 lead ECG was recorded on each study day. 
Statistical analysis of pharmacodynamic data was by repeated 
measures analysis of variance.
3.3. RESULTS
3.3.1. Study of normotensive sub iects
In the supine posture there were no significant 
differences in blood pressure between treatments. A 
significant increase in supine heart rate was observed after 
nifedipine (p < 0.05) with a maximum heart rate of 70.2 + 
11.8 beats/min at 6 hours after dosing compared to 64 ± 7 
after placebo. On standing for 5 minutes nisoldipine 
caused a significant fall in systolic blood pressure, 
maximal at 3 hours with a nadir of 95.6 ± 7.4 mmHg compared 
to 109 ± 6 with placebo (p < 0.05) and 103 ± 9 with 
nifedipine. However, with nifedipine the fall in blood 
pressure did not attain statistical significance. Both 
drugs caused a slight but not significant increase in 
standing heart rate when compared to placebo, maximum 
changes were achieved 6 hours after dosing with 89 ± 12 
beats/min on placebo, 96 ± 17 on nifedipine and 97 ± 12 on 
nisoldipine (Figure 3.1.).
Changes in plasma renin activity, aldosterone and 
noradrenaline were not statistically significant for 
either drug compared with placebo (Table 3.1.-3.2.).
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Fig. 3.1. Erect blood pressure and heart rate (mean + SO) 
after nisoldipine 10 mg , nifedipine
20 mg (■— I), or placebo (o o) in 9 normotensives.
66
table
PRA AND ALDOSTERONE CONCENTRATIONS FOLLOWING ORAL ADMINISTRATION 
OF NIFEDIPINE {20 mg} AND NISOLDIPINE (10 mg)
IN a NORMOTENSIVE SUBJECTS
PLASMA RENIN ACTIVITY (MEAN ± SD) ngAI/ml/hr 
TIME AFTER DOSING
0 2h 4h
Treatment
Nifedipine 2.01 ± 1.0 2.12 ± 1.3 1.58 ± 0.7
Nisoldipine 2.13 ± 1.09 2.36 ± 1.4 1.5 ± 1.0
Placebo 1.89 ± 1.0 1.31 ± 0.5 1.39 ± 0.5
PLASMA ALDOSTERONE (MEAN + SD) pg/ml
TIME AFTER DOSING
0 2h 4h
Treatment
Nifedipine 170.1 ± 57.1 116.1 + 25.7 130.1 ± 35.7
Nisoldipine 121.8 ± 27.0 116.1 ± 37.7 133.6 ± 56.7
Placebo 134.4 ± 53.1 116.1 ± 41.1 121.7 ± 49.9
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Table 3.2. Noradrenaline plasma concentration following oral 
administration of nisoldipine and nifedipine 
in 9 normotensive subjects.
SUPINE PLASMA NORADRENALINE (MEAN ± SD) nm/ 1
Treatment 0 2 4
Nifedipine 1.73 ± 1.13 1.42 ± 0.38 1.61 ± 0.41
Nisoldipine 1.30 ± 0.40 1.45 ± 0.63 1.46 ± 0.74
Placebo 1.28 ± 0.58 1.17 ± 0.38 1.22 ± 0.49
ERECT (5 min) PLASMA NORADRENALINE (MEAN ± SD)
nm/ 1
TIME AFTER DOSING (hrs)
Treatment 0 2 4
Nifedipine 2.18 ± 0.86 2.83 ± 0.73 3.51 ± 1.50
Nisoldipine 2.12 ± 0.81 3.37 ± 0.73 3.02 ± 0.71
Placebo 2.21 ± 0.45 3.04 ± 2.48 2.33 ± 0.93
6 8
Pharmacokinetic parameters in young normotensive 
subjects are shown in Table 3.3. and in Figures 3.2.-
3,3. The terminal elimination half lifes of both drugs 
were similar (127.3 ± 27 min for nifedipine and 124.2 ±
42 mins for nisoldipine) while the low peak 
concentrations and the area under the curve for 
nisoldipine reflect its very high first pass metabolism 
compared to nifedipine.
The only side effect experienced by the subjects was a 
mild frontal headache lasting 2-4 hours but this was less 
frequent with nisoldipine compared to nifedipine (4 out of 9 
compared to 7 out of 9); one subject had a mild headache 
after placebo.
3.3.2. Study of hypertensive patients
On the first day of treatment with 10 mg nisoldipine 
the blood pressure fell between 1 and 6 hours from 172/97 ± 
17/7 mmHg at baseline to a nadir of 1 49/85 ± 16/9 at 2 hours 
after dosing in supine position; and from 177/101 ± 16/13 
at baseline to 144/87 ± 19/10 at 2 hours after 5 minutes 
standing. On the placebo day blood pressure was 180/97 ± 
19/9 at baseline and 178/98 ± 16/8 at 2 hours in supine 
position; baseline standing blood pressure was 172/103 ± 
19/8 and 174/103 ± 19/10 at 2 hours.
The overall supine heart rate was significantly 
increased compared to placebo (p < 0.05) and at two hours 
was 71 ± 10 on the placebo day and 78 + 12 on the acute
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TABLE 3 ^ .
# Pharmacokinetic parameters of nisoldipine
* 10 mg orally in normotensives.
Peak con. 
ng/ml
Time to peak 
min
t.1/2 AUC
min ng min/ml
Mean
SD
1 .78
0.88
1 0 0 .2
36
124.2
42
340.2
163
Pharmacokinetic parameters of oral nifedipine 20mg 
(Adalat Retard) in normotensives
Mean
SD
Peak con 
ng/ml
60.2
21.7
Time to peak 
min
163.3
65.5
t.1/2
min
127.3
26.8
AUC 
ng min/ml
19,793
5,642
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TIME AFTER DOSING (HOURS)
Fig. 3.2. Concentration vs time curve following oral administration 
of nifedipine 20 mg in 9 normotensives (mean + SD).
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treatment day.
At the weekly review in the outpatient clinic supine 
blood pressure showed a significant fall from 186/105 ± 15/8 
at entry to 162/90 ± 15/9 mmHg (p < 0.01) after 1 week and 
161/90 + 9/7 after 2 weeks of treatment. Corresponding 
heart rate showed a slight increase from 85 ± 9 to 93 ± 9 
beats/min after 1 week and was 91 ± 8 at two weeks.
Standing blood pressure was 179/105 ± 16/9 at entry and fell 
to 160/90 ± 13/9 mmHg after 1 week (p < 0.01) and 154/89 ± 
12/9 at 2 weeks. Corresponding heart rates were 91 ± 9 and 
99 + 8 beats/min after 1 week and 92 ± 9 at 2 weeks (Figure
3.4.).
After 4 weeks of treatment the mean arterial pressure 
at baseline, i.e. 12 hours after the previous dose of 10 mg, 
was significantly lower than the baseline values on the 
placebo day (p < 0.05). On the last day of treatment blood 
pressure showed a further fall from pre dosing levels of 
160/93 + 11/8 to 143/83 ± 11/9 (supine) and from 152/97 ± 
12/6 to 132/85 ± 15/11 (standing) at 6 hours after dosing 
(Figure 3.5.). The overall blood pressure fall was 
statistically significant compared to placebo (p < 0.05).
The profiles of heart rate in the erect position were 
significantly elevated when compared to placebo following 
both acute and 4 weeks of treatment (Figure 3.6.). Plasma 
noradrenaline levels showed no significant change after 4 
weeks of treatment (Table 3.4.). Plasma renin activity and 
plasma - aldosterone did not show significant changes after
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Fig. 3.4. Supine and standing blood pressure and heart rate 
during antihypertensive treatment with nisoldipine 
10 mg twice daily (mean + SD).(n=8).
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TABLE 3.4.
Plasma noradrenaline (Mean ± SD) (nrn/L) in essential 
hypertensives after placebo or nisoldipine 10 mg orally.
TIME AFTER DOSING, (hrs)
0 2 4 8
Treatment
Placebo 2.23 0.77 2.03 0.71 1.72 0.74 1.71 0.52
Nisoldipine acute 2.53 1.25 2.57 1.09 1.92 0.86 2.53 0.85
Nisoldipine chronic 3.31 2.46 3.05 1.59 2.7 2.1 2.52 1.29
(4 weeks)
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table
PRA AND ALDOSTERONE CONCENTRATIONS IN 8 HYPERTENSIVES 
DURING NISOLDIPINE TREATMENT
PLASMA RENIN ACTIVITY (MEAN + SD) ng Al/ml/hr 
HOURS AFTER DOSING
Treatment
0 2 4 8
Placebo 1.53 ± 1.8 1.69 ± 1.8 1.64 ± 2.06 1.76 ± 1.36
Nisoldipine
Acute 1.75 ± 1.4 1.42 ± 1.36 1.74 ± 0.97 1.28 ± 0.7
Nisoldipine
Chronic 1.48 ± 1.53 1.72 ±1.67 1.4 ± 1.07 1.76 ± 1.55
PLASMA ALDOSTERONE (MEAN ± SD) pg/ml
HOURS AFTER DOSING
Treatment
0 2 4 8
Placebo 92.5 ± 54.5 88.1 ± 42.2 71.8 ± 43.0 89.6 ± 45.3
Nisoldipine
Acute 87.8 ± 52.6 72.6 ± 35.5 52.7 ± 25.3 70.4 ± 45.6
Nisoldipine
Chronic 82.3 ± 56.6 56.1 ± 22.6 65.2 ± 38.0 84.1 ± 45.0
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acute or chronic dosing when compared to placebo (Table 
3.5.).
Two patients experienced mild frontal headache on the 
placebo treatment day, two had headache after the first dose 
and one on the last study day. Four patients complained of 
facial flushing within two hours of dosing during the first 
week of treatment; this was not apparent after 10-14 days 
and did not require dose reduction or withdrawal from the 
study. Four patients developed mild ankle oedema between 
two and four weeks of treatment; one of them showed a 
moderate weight gain of 2 kg. No patient complained of 
orthostatic symptoms after acute or chronic dosing. There 
were no significant changes in haematological or biochemical 
measurements or on the 12 standard lead E.C.G.
3.4. DISCUSSION
In this group of young normotensive subjects 
nisoldipine caused a significant fall in erect systolic 
blood pressure, confirming its activity as a blood pressure 
lowering agent. The fall in blood pressure appeared to be 
longer lasting than the modest short lived falls previously 
described in some other studies with nifedipine (Millar et 
al, 1983). Indeed in the present study nifedipine did not 
lower blood pressure significantly in this group of young 
subjects but evidence of haemodynamic activity was provided 
by the significant increase in supine heart rate. This is 
not inconsistent with previous reports that nifedipine does
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not significantly reduce blood pressure in healthy young 
subjects (Corea et al, 1980; MacGregor et al, 1982). The 
modest effects which calcium antagonists have on the blood 
pressure in normal subjects has been contrasted with other 
antihypertensive drugs, for example the beta adrenoceptor 
antagonist propranolol and the A.C.E. inhibitor captopril 
(MacGregor et al, 1982), which produce similar blood 
pressure falls in both normotensives and hypertensives.
This has been interpreted as evidence of a cellular 
abnormality, with excessive availability of intracellular 
Ca+* in hypertensives which can be "corrected" by calcium 
antagonist drugs (Buhler, 1983). In addition to the 
presence or the absence of hypertension, age and sodium 
status or plasma renin activity are other factors which have 
been implicated as determinants of the acute blood pressure 
response to nifedipine. In the volunteer study all
subjects were aged less than 30 years and were not on a 
sodium restricted diet. The effect of dietary sodium on 
blood pressure is mediated by the activity of the renin- 
angiotensin system as well as the sympathetic nervous system 
(Vollmer, 1984) and so may well affect the response to 
antihypertensive treatment (Buhier et al, 1984).
The antihypertensive efficacy of nisoldipine was 
demonstrated in a group of patients with essential 
hypertension following both acute dosing and continued 
treatment over 4 weeks. In fact recordings of blood 
pressure 12 hours after the evening tablet showed the
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persistence of a significant antihypertensive effect in both 
the supine and erect postures. There were larger increases 
in heart rate after the first dose than after the last day 
of treatment despite lower blood pressure levels. This is 
consistent with previous reports in the literature of 
tolerance to the acute reflex responses to dihydropyridine 
calcium antagonists probably secondary to resetting of the 
baroreceptors (Littler et al, 1983; Young et al, 1984).
The side effects observed in these patients were similar to 
those reported for other calcium antagonists like nifedipine 
(Lederballe Pedersen et al, 1979). The intensity of 
headache and flushing seemed to be less after the first 
week of treatment. Ankle oedema independent of weight gain 
was observed relatively frequently.
The pharmacokinetic analysis demonstrated that the 
plasma half-life of nisoldipine following single doses is 
not significantly longer than that of nifedipine although 
nisoldipine appeared to have a longer duration of action. 
Previous pharmacokinetic studies with nifedipine have 
shown great interindividual variability in its plasma 
concentrations following oral administration, reflecting 
wide differences in oral bioavailability and first pass 
metabolism (Raemsch and Somner, 1983).
The present results confirm that the disposition of the 
retard formulation of nifedipine differs from that reported 
for the capsule formulation (Banzet et al, 1983). The side 
effects of nifedipine capsules have been correlated with
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high plasma concentrations immediately after dosing.
In addition it has been previously observed that the fall in 
blood pressure during chronic dosing with nifedipine is 
closely related to plasma levels at least in individual 
hypertensive patients (Pasanisi & Reid, 1983). A possible 
explanation for the relatively long duration of action for 
nisoldipine in hypertensives is that active metabolites may 
contribute to its hypotensive effect but there are no data 
to support this hypothesis.
The study of nisoldipine in hypertensive patients was 
an open study and lacked placebo control but it showed 
encouraging antihypertensive effects of nisoldipine which 
deserved further investigation.
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CHAPTER it
VERAPAMIL IN ESSENTIAL HYPERTENSION 
KINETICS, DYNAMICS AND CGNCENTRATION-EFFECT RELATIONSHIP
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4.1. INTRODUCTION
The relationship between blood concentration and effect 
for drugs used in the treatment of hypertension has received 
limited consideration. This may be related to the lack of 
a clear dose-response relationship for some of the commonly 
used drugs, for example, beta blockers (Collste et al, 1976;
Von Bahr et al, 1976).
As the clinical response (i.e. fall in blood pressure) 
is readily detectable, little attempt is made to rationalise 
treatment prospectively because the dosage can be adjusted 
retrospectively. Thus, unlike antiarrhythmic (Meffin 
et al, 1977) and bronchodilator drugs (Whiting et al, 1984), 
clinical pharmacokinetics have been seldom applied to 
improve drug use in hypertension. As a consequence the 
variation in responsiveness to antihypertensive drugs has 
been related only to factors such as age or ethnic origin.
It has been suggested, for example, that the response of 
hypertensive patients to calcium antagonists is not only
quantitatively but qualitatively different from 
normotensives, implicating abnormalities of intracellular 
calcium handling as a primary pathogenic mechanism in 
hypertension (Buhler et al, 1982). These claims have often 
been based on inadequate data with observations being made 
of responses to different doses at different times and with 
no account taken of interindividual and time-related 
differences in plasma drug levels.
In the case of nifedipine a correlation between plasma
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concentrations and fall in blood pressure has not been found 
in a group of patients (Pedersen et al, 1980a) whereas a 
significant correlation was demonstrated by others (Aoki et 
al, 1982b).
In recent years concentration-effeet analysis has been 
developed by different authors (Sheiner et al, 1979; Whiting 
and Kelraan, 1980). This "modelling" technique which seeks 
to explain pharmacological response in terras of the time 
course of a drug in the body (as reflected by blood 
concentration measurements) depends on having sufficient 
data to characterise the response profile associated with 
simultaneously observed drug concentrations. This 
approach has been successfully used to investigate in 
normotensive subjects the effects of acute dosing with alpha 
adrenoceptor antagonists such as doxazosin (Vincent et al, 
1983); trimazosin (Meredith et al, 1983) and labetalol 
(Elliott et al, 1984).
Considering the inter-relationship between drug 
concentration and effect for a calcium antagonist such as 
verapamil, presents more of a problem. The role of this 
drug in the treatment of hypertension is well established 
(Corea et al, 1981; Buhler et al, 1982) but its 
pharmacokinetics are known to change with continued drug 
administration compared to acute dosing (Freedman et al, 
1981; Shand et al, 1981) and there is the possibility that 
the major metabolite of verapamil, norverapamil, may 
contribute to the overall pharmacodynamic profile
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(Neugebauer, 1978). The concentration effect relationships 
following acute and chronic dosing with verapamil in the 
control of essential hypertension were investigated in an 
attempt to further elucidate the factors decreasing the 
response to this calcium antagonist in individual patients.
4.2. PATIENTS AND METHODS
Six mild-moderate essential hypertensive men (age 54 ±
7 years) were studied. They received no antihypertensive 
therapy for at least four weeks prior to the study.
Patients were studied on three days, following placebo 
administration, after acute oral dosing of verapamil 80 mg 
(subject 4 received 160 mg) and then were established on a 
regimen of 80 mg twice daily verapamil (subject 4 received 
160 mg twice daily) for one month. At this time they were 
studied again with the same single dose of verapamil 80 mg 
(subject 4, 160 mg). On each study day blood pressure and 
heart rate were measured supine and standing and blood 
samples were withdrawn at frequent intervals for 8 hours 
after dosing for the determination of plasma levels of 
verapamil and norverapamil according to the procedure 
described in Chapter 2.
The pharmacokinetics of verapamil and its metabolite 
were studied using an integrated model with two compartments 
describing drug disposition and a third compartment for the 
metabolite (Figure 4.1.). Pharmacodynamic profiles were 
initially analysed by application of the trapezoidal rule to
8 6
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Fig, 4.1. Three conpartment model used for evaluation 
of verapamil and norverapamil kinetics. 
Detail^  of equations are given in chapter 7.
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derive to the area under the effect time profiles. 
Concentration-effeet analysis was applied to integrate the 
pharmacokinetic and pharmacodynamic profiles (Meredith et 
al, 1983).
The pharmacokinetic data were related to the 
fall in systolic blood pressure corrected for any placebo 
day response (i.e. the difference in the systolic blood 
pressure after 5 minutes of standing following active 
treatment and placebo administration). The standard 
pharmacokinetic model is augmented by an effect compartment 
that is deemed small enough not to influence the 
pharmacokinetics and is governed by first-order processes. 
The measured effect (fall in blood pressure) is then related 
to the concentration of drug in the effect compartment by 
non linear least squares fitting with equal weighting of the 
points. The three parameters derived from this procedure 
are m, i and where m is the slope which represents the
sensitivity to the drug (i.e. responsiveness = effect or 
change in blood pressure per unit of increase in drug 
concentration in the effect compartment), i is the intercept 
term from the equation relating drug concentrations to 
effect, and is the first-order rate constant which
characterises the concentrâtion-effect disequilibrium. It 
is an integral part of this "modelling" approach that, at 
steady state, drug concentrations in plasma are directly 
related to the pharmacological response and that this steady 
state relationship can be identified by extrapolation from
8 8
analysis of the response to the initial dose of the drug,
4.2.1, Statistical analysis
Blood pressure and heart rate changes were evaluated by 
analysis of variance.
Comparison of kinetic results was made by paired t
test.
4.3. RESULTS
4.3.1. Pharmacodynamics
On the first day of treatment with verapamil supine 
blood pressure fell significantly between 1 and 6 hours from 
168/96 + 15/9 mmHg at baseline to a nadir of 136/77 ± 15/9 
at 5 hours after dosing; and from 162/98 ± 14/10 at 
baseline to 152/89 ± 21/10 at 5 hours in the standing 
position.
Corresponding supine heart rate was 7 8 + 7  beats/min at 
baseline and 69 ± 7 at 5 hours; standing heart rate was 80
i 7 at baseline and 76 + 13 after 5 hours (M.S.). After 1
month treatment predosing supine blood pressure was 162/92 ± 
17/5 and fell to 140/77 ± 15/13 at 5 hours and was 154/79 ± 
21/9 at 8 hours after dosing. Standing blood pressure was 
170/97 ± 17/5 predosing and fell to 150/87 ± 20/12 at 5 
hours. The overall blood pressure fall was statistically 
significant compared to placebo (p < 0.05). Pre-dosing 
heart rate was 69 ± 10 and 63 ± 7 at 5 hours in supine
position. Standing heart rate was 75 ± 12 and 72 ± 12
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respectively (N.S.). The profile of systolic blood 
pressure and heart rate standing is shown in Figure 4.2. 
Placebo corrected standing systolic blood pressure showed a 
sustained fall throughout the day, maximal at 2 hours 
(Figure 4.3.).
Application of the trapezoidal rule to the individual 
placebo corrected effect-time profiles showed a mean fall in 
standing systolic blood pressure of 44 + 10 mmHg.h after 
acute administration and 49 ± 8 after chronic treatment 
(N.S.) (Table 4.1.).
4.3.2. Pharmacokinetics
Mean peak plasma concentration was 121 ± 45 ng/ml after 
acute administration of verapamil and increased 
significantly to 201 + 69 after 1 month treatment (p <
0.01) (Figure 4.4.). Mean time to peak concentration was
1.2 ± 0.6 h after acute dosing and 0.8 + 0.7 after chronic 
dosing (N.S.). Individual data are shown in Table 4.2.
The pharmacokinetic parameters obtained in fitting 
acute and chronic concentration data to a three compartment 
model are given in Tables 4.3. and 4.4. The derived 
pharmacokinetic parameters showed a significant increase (p 
< 0.001) in the area under the concentration time curve (AUC 
dose) for verapamil from 645 ± 304 acutely to 1314 ± 391 
ng.h.ml following chronic dosing. There was also a 
significant increase in terminal elimination half-life for 
the drug ( t1/2) from 4.20 ± 1.48 h to 10.6 ± 6.2 h.
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Fig.4.2. Mean standing systolic blood pressure and heart 
rate during the study day after placebo, 
acute and chronic administration of verapamil 
in 6 hypertensives.
91
CT
X
E
E
f
0 -
10 —
20-
acute
30 -
A chronic
Time (h)
Fig 4.3. Placebo corrected standing systolic blood 
pressure fall after acute and chronic 
administration of verapamil 80mg in a 
representative hypertensive subject. 
Computer derived best fit of the points.
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TABLE 4.1.
AREA UNDER THE PLACEBO CORRECTED FALL IN SYSTOLIC BLOOD 
PRESSURE PROFILE 0=8 AS DERIVED m  THE TRAPEZOIDAL 
RULE, AFTER VERAPAMIL ADMINISTRATION IN 
HYPERTENSIVE PATIENTS
(mmHg.h;
Patient Acute Chronic
1 -34.10 -40.5
2 -61.5 -64.9
3 -50.4 -49.3
4 -42.9 -48.0
5 -33.5 -48.3
6 -47.3 -45.0
Mean
+
S.D.
-44.9
±
10.6
-49.3
±
8.3
MS
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TABLE 4.2.
PEAK VERAPAMIL CONCENTRATIONS AND TIME TO PEAK CONCENTRATIONS 
FOLLOWING ACUTE AND CHRONIC VERAPAMIL TREATMENT 
IN 6 HYPERTENSIVE PATIENTS
Patient Peak Verapamil Time to Peak
Concentration (-tlag)
(ng/ml) (h)
Acute Chronic Acute Chronic
1 87.5 265.2 1.50 0.62
2 156.1 192.3 0.46 0.48.
3 151.8 215.0 0.55 0.50
4 89.5 268.2 1.22 0.58
5 66.2 78.3 2.03 2.30
6 176.0 191.3 1.85 0.62
Mean 121.1 201.7 1.27 0.85
±
S.D.
+
45.4
±
69.4
±
0.65
±
0.71
p < 0.01 NS
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TABLE 4.3.
THE PHARMACOKINETICS OF VERAPAMIL AND NORVERAPAMIL FOLLOWING ACUTE 
ORAL ADMINISTRATION IN 6 HYPERTENSIVE PATIENTS
îtient A
(ng/ml)
a
(1/h)
B
(ng/ml)
B
(1/h)
^a
(1/h)
^1m ^c^^m 
(1/h)
r^ao
(1/h)
tlag
(h)
1 251 0.55 36.9 0.116 1.13 0.73 0.86 0.5
2 144 0.97 94.8 0.202 5.43 0.82 0.94 0.9
3 555 1.64 69.9 0.126 2.73 14.6 24.6 0.45
4 258 0.80 55.4 0.155 1.46 1.92 1.48 0.28
5 534 0.43 358 0.368 0.50 6.10 5.91 1.97
6 298 0.39 183 0.176 0.84 1.45 1.76 0.66
A = coefficient
a = hybrid first order rate constant
B = coefficient
3 = hybrid first order rate constant
kg = first order rate constant
k^ rn = rate constant describing metabolite formation
Vc/Vm = Volume of central and metabolite compartment
kjjjQ = rate constant describing metabolite elimination
tlag = time before drug is detected in the systemic circulation
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TABLE 4.4.
THE PHARMACOKINETICS OF VERAPAMIL AND NORVERAPAMIL FOLLOWING CHRONIC 
ORAL ADMINISTRATION IN 6 HYPERTENSIVE PATIENTS
Patient A
(ng/ml)
a
(1/h)
B
(ng/ml)
6
(1/h)
^a
(1/h)
^^ 1m
(1/h)
^mo
(1/h)
tlag
(h)
1 215 0.60 118 0.08 21.2 0.17 0.19 0.99
2 597 1.33 45.5 0.031 2.83 0.40 0.37 0.50
3 276 0.72 52.6 0.044 24.8 0.88 1.29 0.49
4 256 0.72 101 0.063 14.9 0.55 0.56 2.49
5 284 2.01 121 0.106 1.5 1*97 2.05 1.72
6 329 0.65 39 0.036 2.83 0.73 0.65 0.40
97
No significant change in the relative clearance of 
norverapamil, as judged by the ratio of areas under the 
metabolite and parent drug time curves (kUC^/kUC^) was shown 
(Table 4.5.).
4.3.3. Concentration effect analysis
Concentration effect analysis allows us to characterise 
the dynamic profile on both acute and chronic therapy. 
Initially an attempt was made to model the effect using both 
parent drug and metabolite as described in previous studies 
with alpha adrenoceptor antagonists (Meredith et al, 1983) 
but in all subjects on both acute and chronic study days the 
model attributing effect of parent drug was most 
appropriate, as assessed by the general linear (F ratio) 
test (Bauxenbaum et al, 1974), and therefore used and 
presented here. The effect model parameters for both acute 
and chronic study days are given in Table 4.6.
The rate constant characterises the time course of
the effect following any rapid change in blood concentration 
of drug and thus reflects the onset and offset of drug 
effect. There is wide interindividual variation and in 
some subjects this is large enough to suggest that 
concentration and effect are coincidentally correlated. 
However, in other subjects the is less than 3 which 
suggests that there is a considerable discrepancy between 
drug concentration and peak effect. Despite some 
intraindividual variations there were no significant or
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TABLE 4.B.
DERIVED PHARMACOKINETIC PARAMETERS FOR ACUTE AND CHRONIC ORAL 
ADMINISTRATION OF VERAPAMIL
Patient AUCd
(ng.h/ml)
AUCm/AUCd 3t1/2
(h)
Acute Chronic Acute Chronic Acute Chronic
1 516 1822 0.84 0.91 5.98 8.66
2 575 1682 0.86 1.09 3.43 22.3
3 665 967 0.59 0.66 5.51 15.8
4 464 1941 1.30 0.98 4.47 10.9
5 411 1011 1.03 0.96 1.88 6.56
6 1238 1460 0.82 1.13 3.94 19.3
Mean 645 1314 0.91 0.96 4.20 10.6
+ + + ± ± ± ±
S.D. 304 391 0.24 0.17 1.48 6.2
P < 0.001 NS P < 0.005
AUC^ = area under the curve for the parent drug 
AUC = area under the curve for the metabolite
m
Bt1/2 = terminal elimination half-life
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TABLE 4.6.
COMCENTRATIOM-EFFECT ANALYSIS OF ACUTE AND CHRONIC 
VERAPAMIL - DERIVED PARAMETERS
Slope (m) keq
Sensitivity
(mmHg/ng/ml) (1/h)
Patient Acute Chronic Acute Chronic
1 -0.080 -0.053 3.1 2.0
2 -0.164 -0.151 0.53 0.78
3 -0.112 -0.124 0.73 0.47
4 -0.129 -0.119 2.4 0.32
5 -0.090 -0.081 3.4 1.5
6 -0.053 -0.073 4.6 1.7
Mean
+
S.D.
-0.105
±
0.039
-0.100
+
0.037
2.5
±
1.6
1.13
±
0.70
NS NS
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systematic differences between values on acute and 
chronic study days. The effect model parameter m or slope 
showed similar potency on both study days in terms of blood 
pressure fall per unit drug concentration in blood (Table
4.6.).
4.4. DISCUSSION
Verapamil showed in this small group of patients acute 
antihypertensive activity which was maintained and even 
prolonged throughout the day after 1 month treatment as 
reported by other authors (Leonetti et al, 1980; Corea et 
al, 1981). Heart rate did not change significantly either 
acutely or chronically. A slight reduction of the post­
prandial increase in standing heart rate following verapamil 
administration was observed compared to placebo (Figure
4.1.). A similar attenuation by verapamil of the increase 
in heart rate is more clearly observed in Chapter 6 
following co-administration of prazosin in normal subjects. 
The placebo corrected effect-time profiles showed a similar 
fall in blood pressure on both acute and chronic day.
A significant increase in the area under the curve and 
elimination half-life with chronic dosing was observed as 
reported by other groups (Freedman et al, 1981; Shand et 
al, 1981) and also in this thesis after repeated dosing in 
normal volunteers (Chapter 7).
Simple approaches to analyse the dynamic profiles 
seemed inappropriate due to these changes in kinetics.
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Concentrât ion effect analysis using an effect compartment 
has shown that the responsiveness on acute and chronic 
therapy is similar suggesting that any differences in the 
effect profile are likely to be due to differences in 
pharmacokinetics. The change in although not
significant indicates an earlier and longer lasting effect 
with chronic dosing of verapamil. In conclusion the 
mathematical model applied has shown that a relationship 
between plasma concentration of verapamil and blood pressure 
fall exists and is also maintained with chronic dosing.
For a fixed increase in blood concentration of drug in the 
effect compartment a similar change in blood pressure is 
expected on both acute and chronic treatment. Plasma 
concentration is, indeed, another determinant of verapamil 
antihypertensive activity.
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CHAPTER 5.
EFFECT OF CALCIUM ANTAGONISTS ON ADRENERGIC AND NON 
ADRENERGIC VASCULAR RESPONSES AND PLATELET AGGREGATION
103
VASCULAR PRESSOR RESPONSE AFTER VERAPAMIL AND NISOLDIPINE
5.1. INTRODUCTION
Animal studies have shown that at least two types of 
alpha adrenoceptor contribute to peripheral vasoconstrictor 
tone (Bentley et al, 1977; Drew and Whiting, 1979;
Docherty & McGrath, 1980; Timmermans & van Zwieten, 1980; 
Yamaguchi & Kopin, 1980) and recent evidence from human 
studies supports this view (Kiowski et al, 1983; van 
Brummelen et al, 1983; Elliott & Reid, 1983; Murphy et al, 
1984a). The experimental evidence is that the responses 
mediated via alpha adrenoceptors are dependent upon 
modifications in the transport of Ca++ across cell membranes 
and also by mobilization of intracellular calcium (Bohr, 
1963; Fain & Garcia-Sainz, 1980). It has b^en suggested 
that stimulation of the different post-synaptic alpha- 
adrenoceptor subtypes on vascular smooth muscle may modify 
transmembrane calcium flux by different mechanisms (Van 
Breemen et al, 1982); in particular, that activation of the 
alpha^ receptor is associated with an augmented 
intracellular Ca++ mobilization which is not directly 
inhibited by calcium entry blockers (Langer & Shepperson, 
1982) and that activation of the alphag receptors is 
associated with an increased entry of extracellular Ca++ 
which is inhibited by calcium entry blockers (Van Meel et 
al, 1981). It has been claimed that calcium antagonists 
exert their peripheral vasodilator actions by preferential
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antagonism of alphag receptors (Van Zwieten et al, 1982),
Calcium antagonists drugs have been widely used for the 
treatment of ischaemic heart disease and hypertension. The 
papaverine derivative, verapamil, has shown not only 
peripheral vasodilator activity but also cardiac effects 
with decreased myocardial contractility and atrioventricular 
conduction. In relative contrast dihydropyridine 
derivatives like nisoldipine and nifedipine, exert their 
greatest effects on vascular smooth muscle with little 
direct action on the heart.
These two subgroups of calcium antagonists also have 
different affinities for different tissues and vascular beds 
and furthermore there is evidence that they have different 
actions on calcium channels (Karliner et al, 1982) and 
different effects on alpha adrenoceptor function (Motulsky 
et al, 1983; Saeed et al, 1983).
The first of the studies described in this chapter 
investigates in normotensive males the relationship between 
calcium channels and alpha adrenoceptors and also possible 
differences in the peripheral vascular actions of verapamil 
and the new dihydropyridine, nisoldipine, which has been 
claimed to have a more selective action on the peripheral 
vasculature (Kazda et al, 1980; Knorr, 1982) than its 
analogue, nifedipine.
The second part of this chapter deals with the effects 
of the two drugs on platelet function by investigating 
platelet aggregation and activation which is dependent upon
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both calcium ions and alphag adrenoceptors.
5.2, METHODS
The study was performed on nine healthy normotensive 
males aged 20-40 years, body weight within 10% of ideal 
values (67.6 + 7 kgs).
In a single blind randomised order study the subjects 
received either placebo or verapamil 160 mg orally or 
nisoldipine 20 mg orally for four days. Subjects were 
studied on the first and the fourth day of each treatment 
period. Treatment periods were separated by at least two 
weeks. Studies were undertaken in a quiet temperature 
controlled (20 + 2°C) Clinical Pharmacology Research Unit, 
after an overnight fast, and subjects remained supine 
throughout each study day. Blood pressure and heart rate 
were measured by automatic blood pressure recorder (SENTRON) 
at intervals up to 8 hours after dosing.
Between 1 and 4 hours after drug administration 
vascular responsiveness was assessed by a series of 
intravenous infusions of increasing doses of three pressor 
agents; phenylephrine, a selective alpha^ agonist; alpha- 
methylnoradrenaline, a relatively selective alpha2 agonist; 
and angiotensin II, a non-adrenergic "direct" vasoconstrictor, 
The sequence of the infusions was randomised but kept 
constant for each individual throughout the whole study.
Each agonist was administered by incremental infusion, with 
5 minutes at each of not less than 3 dose levels, until mean
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arterial pressure increased by about 30 mmHg, with limits of 
45 mmHg systolic and 30 mmHg diastolic pressure. The doses 
ranged from 0.5-10 /ig/kg/min for phenylephrine, 0.01-5.0 
^g/kg/min for alpha-methylnoradrenaline and 5.0-150 
ng/kg/min for angiotensin II.
After each infusion subjects rested for 30 minutes 
to allow blood pressure and heart rate to return to within 
± 5 mmHg of basal values of mean arterial pressure 
before the next infusion was started.
5.2.1. Verapamil Assay
Whole blood concentrations of verapamil and its 
metabolite, norverapamil, were determined by HPLC with 
fluorescence detection as described in Chapter 2.
5.2.2. Data analvsis.
The change in blood pressure was plotted against the 
log dose of each agonist and fitted to a quadratic function 
(to include all data points) to derive dose-response curves 
as described by Sumner et al (1982). The dose of agonist 
required to raise mean arterial pressure by 20 mmHg (PD20) 
was obtained by interpolation from each individual curve and 
the dose ratios calculated for each treatment when compared 
to placebo. Data were submitted to log transformation (which 
was shown to satisfy statistically the assumptions of 
constant variance and normality of distribution ) and 
treatments were compared by paired t-test with Bonferoni
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correction,
5.3. RESULTS
The baseline (pre-treatment) blood pressures and the 
control (pre-infusion) blood pressures are shown in Table
5.1. There were no significant differences between the 
different study days.
The results of the pressor response studies are shown 
as the computer fitted mean curves in Figures 5.1. - 5.3. 
and are summarised in Table 5.2. with statistical evaluation 
based on comparisons of individual curves.
5.3.1. Phenylephrine
The pressor responsiveness to phenylephrine was 
significantly altered, with progressive shifts to the right 
of the log dose pressor response curves after both acute 
(1st day) and multiple dosing (4th day) of treatment with 
both drugs (Figure 5.1.). The mean PDgQ following placebo was 
2.5 /Ig/kg/min and this was significantly increased to 4.6 
following the first dose of verapamil and to 6.4 ][ig/kg/min 
following 4 days of verapamil (p < 0.01). Following 
nisoldipine, both acute treatment with a mean PD20 of 6.4 
and 4 days of treatment with a mean PD20 9.9 jLig/kg/min 
were significantly different (p < 0.02) from placebo.
There were no significant differences between the two drugs.
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TABLE 5 . 1 .
SUPINE BLOOD PRESSURE FOLLOWING VERAPAMIL AND NISOLDIPINE 
ADMINISTRATION IN £ SUBJECTS 
(MEAN ± SD)
PLACEBO VERAPAMIL NISOLDIPINE
Acute "Chronic" Acute "Chronii
Baseline 120/67 122/67 120/68 120/65 118/65
0 hours ± 9/9 ± 9/6 ± 5/7 ± 8/7 ± 7/9
Pre- 116/67 113/56 114/62 115/61 115/63
Angiotensin ± 7/6 ± 8/7 ± 7/5 ± 8/6 ± 9/8
Pre- 114/64 115/61 114/65 117/63 116/60
Phenylephrine± 6/5 ± 7/6 ± 7/5 ± 6/5 ± 8/7
Pre- 119/67 116/64 116/61 114/62 114/61
Alphamethyl- 4 5/7 ± 7/7 ± 6/5 ± 8/7 ± 6/8
noradrenaline
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t a b l e
PRESSOR RESPONSES TO PHENYLEPHRINE, ALPHAMETHYLMORADREMALINE 
AND ANGIOTENSIN II INFUSIONS IN £ SUBJECTS AFTER VERAPAMIL 
AND NISOLDIPINE ADMINISTRATION 
MEAN + SD
Alpha
Methylnor-
Phenylephrine adrenaline Angiotensin II
PLACEBO PD20 2.45 ± 1 .54 0.54 + 0.37 30 ±24.6
VERAPAMIL
Acute PD20 4.59 + 2.78 0.54 + 0.4 54.3 ±32.5
D.R * 2.1 + 1 .2 0.9 + 0,3 * 2.4 ± 1.7
Chronic PD20 5.41 + 3.39 0.74 ± 0.7 109.5 ±70.1
D.R * 3.0 + 1 .6 1.1 ± 0.6 » 4.6 ± 3.5
NISOLDIPINE
Acute PD20 6.36 ± 3.39 0.46
+ 0.29 67.6 ±44.6
D.R * 3.1 ± 2.1 0.9 ± 0.3 * 2.4 ± 1.2
Chronic PD20 9.94 ± 13.4 1.08
+ 1 .08 91 ±97.7
D.R * 3.6 ± 1.9 * 1.7 ± 0.6 * 3.1 ± 1.6
* = p < 0,05 compared to placebo.
PDpQ = the dose required to increase blood pressure by 20 mm 
Hg.
D.R = Dose ratio = the ratio between the PDpQ for each 
active treatment and the PDgQ for placebo.
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VERAPAMIL -  Day 4
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in M.A.P. 
mmHg
NISOLDIPINE -  Day 4
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Phenylephrine
0.5 1.0 2.5 5.0 10 pg/Kg/min
Fig.5.1. Mean pressor dose-response curves for phenylephrine 
(9 subjects). Responses for all treatments.
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5.3.2. Alpha-methvinorad renaline.
The pressor responsiveness to alpha-methylnoradrenaline 
showed a similar pattern but the shifts to the right of the 
log dose pressor response curve particularly after the first 
dose administration of the two drugs were modest (Figure
5.2.). Only after 4 days of nisoldipine was a significant 
shift obtained: PD20 1.1, compared to 0.5 pg/kg/min
after placebo, and this shift was also significantly 
greater than that observed with the first dose of 
nisoldipine (p<0.05).
5.3.3. Angiotensin II
Both active treatments modified the pressor 
responsiveness to angiotensin II shifting the dose-response 
curves to the right (Figure 5.3.). These shifts were both 
marked and statistically significant following continued 
therapy with both drugs: the mean PD20 110 after
verapamil and 91 ng/kg/min following nisoldipine, compared 
to 30 ng/kg/min after placebo.
5.3.4. Drug concentration-effect relationships
There were significant relationships between the whole 
blood verapamil concentrations and the dose ratios for 
phenylephrine (r = 0.63; P < 0.01) and for angiotensin II 
(r = 0.61; p < 0.05). There was no such correlation for the 
more modest shifts after alpha-methylnoradrenaline. The 
inclusion of norverapamil concentrations in these analysis
1 12
In crease  in
VERAPAMIL -  Day 4
Systolic Pressure PLACEBO '
NISOLDIPINE -  Day 4
mmHg30
20
AlphaMethy (Noradrenaline 
2.0 pg/Kg/min0.1 0.50.2 1.0
Fig.5.2. Mean pressor dose-response curves for 
alpharnethylnoradrenaline (9 subjects). 
Response for continued administration 
with verapamil and nisoldipine corpared 
with placebo.
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Fig.5.3. Mean pressor dose-response curves for angiotensin II (9 subjects) 
Responses for all treatments.
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did not significantly improve these correlations.
5.4. DISCUSSION
Previous studies in man have shown that calcium channel 
blocking drugs impair the pressor response to the "direct" 
vasoconstrictor angiotensin II (Vierhapper et al, 1982; 
Millar et al, 1983) and the results of this study confirm 
such a peripheral effect for both verapamil and nisoldipine, 
particularly with continued administration. After the 
first dose of each drug, however, interference with 
angiotensin-induced vasoconstriction tended to be more 
marked with nisoldipine and this may be an indication of its 
greater selectivity for peripheral vascular sites.
The relationship between alpha adrenoceptors and the 
activation of calcium channels has not been well defined in 
man. Impairment of adrenergic responsiveness to 
noradrenaline has been previously ascribed to a "non­
specific" effect of calcium channel blockade rather than a 
direct effect on alpha adrenoceptors. In this study, both 
verapamil and nisoldipine caused significant shifts in the 
pressor responses to alpha agonists. This was most obvious 
with the alpha^ agonist phenylephrine where there were 3- 
fold shifts in the PDgo both drugs. Because of its
relatively lesser selectivity for peripheral vascular smooth 
muscle the alpha^ antagonist activity of verapamil (Motulsky 
et al, 1983) has been previously attributed to a less 
specific calcium antagonist action for this particular drug.
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The results in this study, however, indicate that a 
comparable alpha-j antagonist effect was obtained with 
nisoldipine for which there is no other direct evidence of 
alpha^ antagonist properties. Similar conclusions were 
reached in a recently published study on alpha adrenoceptor 
antagonist activity of nifedipine (Murphy et al, 1984b).
It has been suggested that activation of peripheral 
alpha2 adrenoceptors is specifically linked with 
transmembrane calcium fluxes and the actions of calcium 
antagonists (van Meel et al, 1981; van Zwieten et al, 1982; 
Timmermans et al, 1983) and so the pressor responses to an 
alpha2 agonist might have been expected to show the most 
marked changes. Alpha-methylnoradrenaline has relatively 
selective alpha2 agonist properties (Starke et al, 1975; 
Starke, 1977) and pressor responses to
alphamethylnoradrenaline have been shown to be markedly 
attenuated in man by the selective alpha2 antagonist 
idazoxan (Elliott and Reid, 1983). However, only after 4 
days treatment with nisoldipine was a significant shift in 
the dose-response curve for alpha-methylnoradrenaline 
observed. The overall effects of both calcium antagonists 
were more marked on the alpha^-mediated responses and the 
non-adrenergic response to angiotensin II, compared to their 
effects on the alpha2«mediated responses. These results 
are consistent with those reported with nifedipine which has 
also been shown to have an adrenergic antagonist action 
without demonstrable selectivity for alpha2 adrenoceptors in
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both animals (Alabaster and Solca, 1985) and man (Murphy et 
al, 1984b).
Although apparent selectivity of alpha2 receptor 
mediated pressor responses has been demonstrated in several 
species (van Zwieten et al, 1982) there is now considerable 
doubt as to the interpretation of these findings. It has 
been shown in animals that alpha^ mediated responses become 
sensitive to the action of calcium antagonists following 
pre-treatment with phenoxybenzamine (Ruffolo & Yaden, 1984) 
and this would be consistent with other observations that 
"spare" receptors of the alpha-j sub-type may be present in 
vascular muscle whereas the reserve capacity of alpha2 
receptors is limited so that there is a closer link between 
response and alpha2 receptor number (Hamilton et al, 1983). 
Alternative explanations include differences in sensitivity 
between full agonists, like alpha-methylnoradrenaline, and 
partial agonists or even differences between 
phenylethylamines and imidazolines in their binding to 
receptors or post-receptor mechanisms and associations with 
calcium channels.
In conclusion, this study demonstrates in man that 
adrenergic responses mediated via both alpha-j and alpha2 
receptors are affected by calcium antagonist drugs. There 
was no evidence with either verapamil or nisoldipine that 
this effect was specifically linked to the alpha2 
adrenoceptor.
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VERAPAMIL, NISOLDIPINE AND PLATELET AGGREGATION
5.5. INTRODUCTION
Calcium ions are involved in several stages of platelet 
activation including platelet adhesion to endothelium, 
platelet shape change, the excitation contraction coupling 
in the release of vasoactive substances and the synthesis of 
the metabolites of arachidonic acid (Ardlie, 1982).
Similarities exist between the role of calcium in 
platelet activation and in contraction of vascular smooth 
muscle where it has been shown that calcium antagonist drugs 
will reduce both the entry of calcium associated with 
agonist activation (Rosenberg et al, 1979; Vanhoutte,
1982a) and the mobilisation of intracellular calcium from 
sites of storage (Wang et al, 1984).
Since platelet abnormalities have been found in both 
hypertension (Mehta and Mehta, 1981) and ischaemic heart 
disease (Burns and Frishman, 1983) the antiplatelet actions 
of the calcium antagonists may expand the therapeutic role 
of these agents (Barnathan et al, 1982).
5.6. SUBJECTS AND METHODS
From the subjects participating in the study described 
in the previous section of this chapter a blood sample was 
withdrawn 1 hour after either drug or placebo administration 
to assess platelet aggregation.
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5.6,1. Platelet preparation and aggregation
Venous blood samples were anticoagulated with 0.1% W/V 
3.28% sodium citrate and centrifuged at 180 g for 15 minutes 
at 20°C to prepare platelet rich plasma (PRP). Platelet 
poor plasma was prepared by further centrifugation of the 
remaining blood at 1700 g for 15 minutes. Platelet 
aggregation was quantified by the turbidometric method of 
Born (1962). The change in optical density through the 
samples was measured in a Payton dual channel aggregometer. 
Aggregation studies were performed at platelet counts of 
300 X 10^/L adjusted by platelet poor plasma after counting 
in a Coulter counter at a wavelength of 880 nM.
In vitro additions were made of adenosine diphosphate 
CADP)(Sigma Chemical Company) or (l)-adrenaline 
bitartrate (Sigma Chemical Company) dissolved in 0.9% saline 
with ImM ascorbic acid and diluted from stock solution 
stored at -70°C. A dose response curve to adrenaline was 
produced by plotting the concentration of adrenaline (11-12 
concentrations) against the maximum rate of aggregation and 
the results fitted by an iterative technique to a 
generalised model of the Hill equation to obtain parameter 
estimates for maximum aggregation (R^ax^ and the 
concentration of adrenaline required to produce 50% maximum 
aggregation (C^q /IM). For determination of inhibitory 
responses the response was plotted against the concentration 
of antagonist required to cause 50% inhibition, at agonist 
concentrations of 1 /xM for adenosine diphosphate and 5 fiM
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for adrenaline. Verapamil powder was dissolved in 0.9% 
saline and nisoldipine powder in 1% ethanol in platelet poor 
plasma. All experiments with nisoldipine were performed 
under sodium light as this dihydropyridine is photolabile.
5,6.2. Aloha^-adrenoceptor binding assay
Platelet rich plasma was spun at 1700 g for 15 minutes 
at 4°C to produce a platelet pellet. The pellet was 
suspended in 0.1% EDTA 150 m M NaCl pH 7.4 to give a 
platelet concentration of 100 x 10^ platelets/ litre.
Whole platelet suspensions (0.8 ml) were incubated for 20 
minutes at 25°C with 6.5 nM ^H yohimbine in triplicate with 
varying concentrations of nisoldipine and verapamil. Non 
specific binding was defined by 1 /iM phentolamine; 
incubations were terminated with 20 ml of ice cold Tris 
(50mM pH7.4) through a Millipore multiport filtration 
apparatus on to Whatman GFC filters and bound radioactivity 
determined by liquid scintillation counting. The was 
calculated from the IC^Q values for inhibition of binding of 
the alpha2 adrenoceptor ligand ^H yohimbine which were found 
from dose response curves for verapamil inhibition of ^H 
yohimbine binding and converted into values according to 
the equation of Cheng and Prussof (1973):
S/Kp + 1
IC^Q is the concentration of the competing agent which
1 2 0
inhibits specific yohimbine binding by 50%. S is the 
concentration of yohimbine in the assay (6.25 nM) and Kp 
is the equilibrium dissociation constant for yohimbine 
binding determined from saturation experiments from the six 
subjects whose blood was used in the displacement K^nM (2.42 
±  1.02, n = 6).
5.6.3. Statistical Analvsis
Statistical analysis was by paired Student's 't' 
test with p < 0.0125 taken as significant to allow 
for multiple comparisons (Ingelfinger et al, -1983). All
results are expressed as mean + standard deviation.
5.7. RESULTS
5.7.1. In Vitro Studies
Platelet Aggregation
Verapamil inhibited the aggregatory response to 
adrenaline. The IC^q was 16.8 + 2.6 /xM. The aggregatory 
response to adenosine diphosphate was also inhibited but the 
concentration to inhibit the response by 50% was over 40- 
fold higher at 723 ± 102 uM (Figure 5.4.). Nisoldipine at a 
concentration of up to 100 uM had no effect on the primary 
aggregatory response to adrenaline concentration range but 
caused a 67% ± 13^inhibit ion of the secondary aggregation 
response to 5 /xM adrenaline (Figure 5.5.) when compared with 
the control response in the presence of vehicle. There was 
no alteration of aggregatory response to 1 /xM adenosine
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Fig, 5.4. The percentage inhibition by verapamil of the
primary aggregation response to adrenaline (5 d|VI) 
(•) and the threshold response to adenosine 
diphosphate (1 pM) (p) in 6 subjects.
1 2 2
1 m m
Fig, 5.5. A representative platelet aggregation tracing 
for the inhibition of secondary platelet 
aggregation by nisoldipine; the ordinate 
represents optical density (O.D.) and the 
time scale of 1 min. marked on the abscissa. 
Top tracing adrenaline (5 ^  arrow) in the 
presence of nisoldipine ( 100 jiM) (®).
Bottom tracing adrenaline (5 uM arrow) in the 
presence of vehicle (o).
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diphosphate,
Radioligand Binding
Verapamil inhibited the binding of C^H] yohimbine to 
platelets with an IC^q of 2.73 ± 0.26 uM ( K = 0.75 uM) 
whereas nisoldipine did not affect yohimbine binding 
(Figure 5.6.).
5.7.2. In Vivo Studies 
Platelet Aggregation
Neither nisoldipine nor verapamil had any significant 
effect on the aggregatory responses to adenosine diphosphate 
either after acute dosing or after 4 days treatment (Table
5.3.). Verapamil for 4 days altered the aggregatory dose 
response curve to adrenaline with significant reductions in 
both the maximal rate of aggregation from 47 ± 18 to 28 + 16 
OD/min (p < 0,002) and increases in the C^q for adrenaline 
induced aggregation from 0.77 ± 0.25 to 1.14 ± 0.54 M (p < 
0.003). Nisoldipine after 4 days caused an increase in the 
C^Q value but no change in the maximal rate of aggregation 
(Figure 5.7.).
Plasma Levels of Verapamil
There were no significant correlations with plasma 
levels of verapamil or its metabolite, norverapamil, 
and the changes in platelet aggregation (C^q or E^^x).
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Fig. 5.6. Verapamil and nisoldipine displacement
of specifically bound tritiated-yohimbine 
to whole platelets: verapamil (•) and 
nisoldipine (o).
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TABLE
PLATELET AGGREGATION RESPONSES TO 1 uM ADENOSINE DIPHOSPHATE 
AFTER ADMINISTRATION OF VERAPAMIL AND NISOLDIPINE 
IN 6 SUBJECTS 
( A O.D. MEAN ± ^
ACUTE CHRONIC
PLACEBO 32 ± 12 33 ± 13
VERAPAMIL 28 ± 13 26 ± 14
NISOLDIPINE 24 ± 13 23 ± 13
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Fig.5.7. The effects of placebo (o),the first dose (•) and 
4 days treatment (a ) with verapamil or nisoldipine 
on platelet aggregation in vitro induced by adrenaline 
expressed as the maximum rate of primary aggregation 
upper (Emax A OD min"' ),and the concentration of 
adrenaline to achieve 50% of maximal aggregation 
C-«(|jM) lower, p values refer to significance levels 
obtained by comparing placebo with 4 day treatment 
values by paired t test. No significant difference 
was found between the Emax values with nisoldipine 
treatment.
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5.8. DISCUSSION
The effects on platelet aggregation of verapamil and 
the dihydropyridine nifedipine have been examined in vitro 
in both animals and man (Johnsson, 1981; Kiyomoto et al, 
1983). It has been shown that platelet aggregation induced 
by adenosine diphosphate is relatively resistant to 
inhibition by both verapamil and nifedipine. The results 
obtained in this study confirm these findings in vitro and 
in vivo. This suggests that adenosine diphosphate triggers 
platelet aggregation through pathways which are not 
sensitive to blockade by calcium channel blockers. The 
role of calcium in adrenaline-induced platelet aggregation 
is under debate. Some authors using ^^Ca and 
chlortetracycline (Owen et al, I98O), the calcium 
fluorescent probes Quin II (Erne et al (1983) and aequorin 
(Johnson et al, 1983) have shown that adrenaline induced 
platelet aggregation is associated with calcium influx.
Other authors have shown no change in platelet calcium 
during adrenaline activation in calcium free media with Quin 
II (Bryden et al, 1984). The present study shows that 
caution must be exercised when using verapamil to examine 
whether or not pharmacological responses are calcium 
dependent. The inhibition of the adrenaline response by 
verapamil cannot be used to resolve this question since 
verapamil has been shown to have other properties in 
addition to its calcium channel blocking effects, with 
activity as an alpha^ and muscarinic antagonist in rat
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myocardium (Karliner et al, 1982). Other authors using a 
different ligand have also found an interaction between 
verapamil and human platelet alpha2 adrenoceptors using [^H] 
RX78IO94 to measure platelet alpha2 adrenoceptor number 
(Maisel et al, 1984). Verapamil has also been reported to 
act as an antagonist to platelet activating factor (PAF) 
induced calcium changes in platelets (MacIntyre and Shaw, 
1982). Similarly caution must be used when interpreting 
the effects of nisoldipine in inhibiting the secondary phase 
of platelet aggregation. The related dihydropyridine 
nifedipine has been shown to be a thromboxane.A2 antagonist 
(Addonizio et al, 1982). Platelets possess adrenoceptors 
of the alpha2 subtype as detected by yohimbine binding 
(Motulsky et al, 1980). The demonstration of the inhibition 
of specific yohimbine binding could be due to a direct 
interaction with alpha2 adrenoceptors or to steric hindrance 
due to the proximity of receptor operated calcium channels. 
The potency of verapamil as an alpha2 blocker at platelet 
alpha receptors is similar to that observed with 
phenoxybenzamine (Brodde et al, 1982). The results of the 
clinical study in which oral dosing was continued for 4 days 
show that a significant inhibition of the aggregatory 
response to adrenaline, but not to adenosine diphosphate, 
may occur after both verapamil and nisoldipine in vivo in 
man. The peak plasma concentration measured during 
verapamil therapy was 10-fold less than the concentration 
required to inhibit specific yohimbine binding in vitro by
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50%. Although there was some accumulation of the 
metabolite, norverapamil, during continued dosing this is 
less active at inhibiting platelet aggregation. The 
discrepancy between the effects during multiple dosing and 
the effects in vitro might also be due to accumulation of 
drug within the platelet. Alternatively, chronic ingestion 
of these agents may deplete intracellular calcium as has 
been reported with other antihypertensive agents (Erne et 
al, 1984).
In summary, the antiplatelet actions of both verapamil 
and nisoldipine may have implications for the primary 
prevention of atherosclerosis and the prevention of platelet 
mediated thrombosis in the treatment of hypertension and 
ischaemic heart disease. However, although adrenaline- 
induced platelet aggregation can be inhibited in vitro by 
both verapamil and nisoldipine, the evidence of this study 
indicates that the antiplatelet effects in vivo are mediated 
by a different mechanism.
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CHAPTER 5
STUDIES ON THE PHARMACODYNAMIC AND PHARMACOKINETIC 
INTERACTIONS BETWEEN VERAPAMIL AND PRAZOSIN
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6.1. INTRODUCTION
The peripheral vasodilator action of the calcium 
channel blocker, verapamil, is not associated with a reflex 
increase in cardiac output, even after acute dosing.
This is in part due to its also having a depressant effect 
on myocardial contractility and atrioventricular conduction 
(Rowland et al, 1979).
In contrast, the antihypertensive drug prazosin, a 
selective antagonist of peripheral vascular alpha-j 
adrenoceptors (Graham et al, 1977) has an acute hypotensive 
effect which is associated with reflex increases in heart 
rate and cardiac output (Lund Johansen, 1980). Thus, the 
combined use of verapamil and prazosin may have therapeutic 
advantages with an additive peripheral vasodilator action 
and a counterbalancing of verapamil’s cardiac depressant 
effect with the reflex cardiostimulant effect of prazosin. 
However, these drugs may also interact in other ways. There 
is evidence that some types of Ca^+ channels are closely 
linked to alphag adrenoceptors (Van Meel et al, 1981) and 
also that Ca^^ fluxes are also mediators of the 
vasoconstrictor response to alpha-j adrenoceptor stimulation 
(Vanhoutte, 1982a). The practical consequences of combined 
calcium channel blockade and alpha-j adrenoceptor antagonism 
have not been adequately established. Furthermore, in 
addition to the potential pharmacodynamic interctions there 
may also be pharmacokinetic interactions. Both verapamil 
and prazosin undergo extensive first pass metabolism
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following oral administration (Schomerus et al, 1976;
Taylor et al, 1977) and there may be competition for hepatic 
uptake or pathways of metabolism, and there may also be 
modification of hepatic or splanchnic blood flow.
In this chapter the blood pressure and heart rate 
responses to oral administration of verapamil and prazosin, 
alone and in combination have been evaluated. The effect 
of combined therapy on the pharmacokinetics of the individual 
drugs has been investigated.
6.2. SUBJECTS AND METHODS
Eight healthy normotensive males, aged 20-40 years, 
gave written informed consent to take part in a double 
blind, randomised, crossover study. They reported to the 
Clinical Pharmacology Research Unit at 8.30 am on each study 
day, at weekly intervals, to receive the following oral 
treatments, in random order;
1) Verapamil 160 mg (+ placebo prazosin)
2) Prazosin 1 mg (+ placebo verapamil)
3) Prazosin 1 mg + verapamil 160 mg.
4) Placebo prazosin + placebo verapamil
Blood samples were withdrawn via an indwelling intravenous 
cannula in a forearm vein for subsequent drug and hormone 
assays.
6.2.1. Blood Pressure and Heart Rate.
Blood pressure was measured by semi-automated recorder
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after a minimum of 10 minutes recumbency prior to 
each supine reading. On standing, readings were taken after 2 
and 5 minutes. The standing period was curtailed if the 
subject complained of orthostatic symptoms or if the 
systolic blood pressure fell to under 80 mmHg, The 
corresponding heart rates were measured by one minute radial 
pulse count. Blood pressure and heart rate were determined 
at baseline and at 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4, 5,
6, 7, and 8 hours after dosing.
6.2.2. Plasma Noradrenaline. Renin and Aldosterone
Venous samples were collected for noradrenaline (supine 
and 5 minutes erect) and for renin activity and aldosterone 
(both supine) at 0, 2, 4 and 8 hours.
Hormones were assayed as described in Chapter 2.
6.2.3. Drug Assavs.
Prazosin, verapamil and norverapamil were measured by 
high performance liquid chromatography with fluorescence 
detection as described in Chapter 2.
6.2.4. Pharmacokinetic analvsis
The choice of pharmacokinetic model was determined 
according to the General Linear (F ratio) test (Boxenbaum et 
al, 1974) whereby the most appropriate fit is statistically 
confirmed by comparison of the weighted sum of squares.
The pharmacokinetics of prazosin were most appropriately
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fitted by a one compartment model described by the following 
equation :
C - A ( e”  ^ — 0—ka ( t—11 ag ) ^
The analysis was carried out using computer-assisted least 
squares fitting with an inverse weighting of drug 
concentrations.
The pharmacokinetic profiles of verapamil and 
norverapamil were most appropriately fitted to an integrated 
three compartment model. The disposition of drug and
metabolite was described by the following equations;
= Ae"^t-tlag) ^ gg-3(t-tlag) _ (A+B)e~ka(t-tlag)
and
Cm
m
t-t^ag) _ e-kmo(t-tiag) +
(e-B(t-tiag) _ e-kmo't-tiag)
- G
<A + B ) ^  .
_________m_______
” ^mo
(e-ka(t-ti^g) _ e-kmo(t-tiag))
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The data were fitted simultaneously to these 
equations using non linear least squares fitting regression 
analysis. Parameters derived from this approach are the 
coefficients (A+B); the hybrid first order rate constants 
for drug disposition ( ot + 3 ) and absorption (ka); the first
order rate constant describing metabolite elimination (k^^);
V
and the constant, ,k1 m where and are the volumes of
m
the central and metabolite compartments respectively.
6.2.5. Statistical Analvsis:
Student paired t test with Bonferoni correction was 
used in the comparisons of the kinetic parameters. 
Statistical evaluation of the pharmacodynamic measurements 
was by repeated measures analysis of variance.
Results are expressed throughout as mean ± S.D.
6.3. RESULTS
6.3.1. Blood Pressure:
Supine blood pressure (systolic and diastolic) 
following each treatment is shown in Figure 6.1.
Compared to placebo, neither verapamil nor prazosin had a 
significant effect on supine blood pressure whereas the 
combination of verapamil and prazosin caused a significant 
reduction (p<0.05) which was maximal between 2 and 6 hours 
with a nadir of 100 + 9 for systolic blood pressure and 60 ±  
7 mmHg for diastolic.
On standing, blood pressure fell with prazosin but not
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Fig.6.1. Mean supine systolic and diastolic blood 
pressures in 8 normotensive subjects.
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with verapamil alone. The lowest systolic pressure with 
prazosin was 99 + 17 at 4 hours compared to 114 + 9 with 
placebo and 110 ± 8 mmHg with verapamil (Figure 6.2.).
The corresponding pressure with the combination was 89 ± 13 
mmHg, The overall hypotensive effect of the combination 
was greatest (p < 0.05) and in addition the reduction in 
blood pressure occurred earlier (within 0,5 hours) and 
persisted for longer (up to 7 hours).
The pattern of diastolic response was comparable 
and is shown in figure 6.2.
6.3.2. Heart Rate
There was a significant increase in supine heart rate 
(Figure 6.3.) following prazosin alone compared to placebo 
(p < 0.05). With verapamil alone there was no significant 
change. The greatest increases in supine heart rate 
occurred within 2 hours of dosing with the combination, 
maximal at 1 hour at 78 + 9 bpm, compared to 72 ± 11 with 
prazosin. Over the 8 hours, however, the combination 
caused less increase than prazosin alone. On standing 
(Figure 6.4.), significant increases in heart rate occurred 
with prazosin alone and with the combination (p < 0.05).
The tachycardia following prazosin alone reached a maximum 
of 1 1 2 ±. 6 bpm at 5 hours after dosing The combination also 
caused a significant increase in heart rate to a maximum of 
102 ± 9 beats/min but it was less than with prazosin alone.
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Fig. 6.4. Mean standing heart rate in 8 normotensive subjects.
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6.3.3. Side Effects
The frequency of orthostatic symptoms was increased 
when prazosin and verapamil were given together. Six 
subjects complained of postural symptoms or had a systolic 
pressure less than 80 mmHg at 18 times between 1 and 6 hours 
after the combination. After prazosin alone postural 
hypotensive episodes occurred on 11 occasions. With 
verapamil only a single subject had orthostatic symptoms and 
with placebo there were no hypotensive problems.
6.3.4. Noradrenaline^ Renin. Aldosterone
Supine and erect plasma noradrenaline levels were 
significantly (p<0.05) increased after prazosin and the 
prazosin plus verapamil combination, particularly at 2 hours 
after dosing (table 6.1.). The greatest increase was 
observed with the combination. Similarly plasma renin 
activity was increased by the combined treatment more than 
by prazosin alone with values still elevated 8 hours after 
dosing (p<0.05)(table 6.2.). Plasma aldosterone showed a 
slight increase 4 hours after combined treatment only.
6.3.5. Pharmacokinetics
The derived pharmacokinetic parameters obtained by 
fitting the verapamil and prazosin concentrations to the 
appropriate models are summarised in tables 6.3. and 6.4. 
There were no significant differences in the disposition of 
verapamil or norverapamil when the drug was given alone or
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TABLE 6.1
NORADRENALINE PLASMA CONCENTRATIONS AFTER ADMINISTRATION 
OF VERAPAMIL AND PRAZOSIN IN 8 MORMOTENSIVES
SUPINE PLASMA NORADRENALINE (MEAN + SD) nmol/1 
HOURS AFTER DOSING
Treatment
0 2 4 8
Verapamil 2.05 ± 1.2 2.11 ± 0.8 2.03 ± 0.4 2.08 ± 0.8
Prazosin 2.64 ± 1.2 3.45 ± 1.1 3.4 ± 1.3 3.98 ± 2.0
Verapamil 
+ prazosin 2.01 ± 1.5 5.01 ± 2.8 3.53 ± 2.1 2.46 ± 1.9
Placebo 2.31 ± 0.6 2.66 ± 1.2 2.48 ± 0.7 2.4 ± 0.9
ERECT 1i^ LASMA NORADRENALINE (MEAN + SD) nmol/1
HOURS AFTER DOSING
Treatment
0 2 4 8
Verapamil 3.67 ± 1.6 5.5 ± 2.4 5.3 ± 1.5 5.68 + 2.7
Prazosin 4.67 ± 3.0 8.04 ± 5.0 7.17 ± 3.5 7.08 ± 3.4
Verapamil 
+ prazosin 4.77 ± 3.2 9.08 ± 4.2 6.6 ± 3.6 7.56 ± 4.6
Placebo 4.85 ± 1.8 5.65 ± 2.1 5.53 ± 2.0 5.18 ± 2.1
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TABLE 6.2.
PRA FOLLOWING ADMINISTRATION OF VERAPAMIL AMD PRAZOSIN 
IN 8 MORMOTENSIVES
SUPINE PLASMA RENIN ACTIVITY (MEAN ± SD) ng ANGI/ml/hr
HOURS AFTER DOSING 
0 2 4 8
Treatment
Verapamil 4.5 ± 3.7 6.8 ± 5.3 4.1 + 2.6 5.5 ± 5.3
Prazosin 3.7 ±1.4 5.5 ± 2.3 5.6 ±2.9 7.4 ± 4.9
Verapamil
+ prazosin 4.0 ±1.8 12.3 ± 7.4 10.6 ±6.5 .11.0 + 6,7
Placebo 5.1 ± 2.5 4.6 ± 3.2 4.83 ± 3.4 6.1 ± 4.2
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TABLE 6 . 4 .
PHARMACOKINETIC PARAMETERS OF PRAZOSIN ALONE AMD COMBINED WITH
VERAPAMIL IN 8 MORMOTENSIVES 
(MEAN +
min
AUC
ng/ml/min
Peak
Concentration
ng/ml
ALONE
162 1601 5.17
COMBINED
P <
38
144
19
M.S.
189
2592
±
919
0.02
0.71
9.64
±
3.58
0.02
146
when co-administered with prazosin. In contrast the 
pharmacokinetics of prazosin were significantly altered by 
the co-administration of verapamil, illustrated by the 
concentration-time profiles in Figure 6.5. The area 
under the prazosin concentration time curve was 
significantly increased (p<0.02) by 62%, from 1601 to 2592 
ng/ml/min when verapamil was administered concurrently.
The peak concentrations of prazosin were also significantly 
higher with the combination (5.2 ng/ml for prazosin alone 
compared to 9.6 ng/ml for the combination p< 0.02). The 
absorption rate constant Ka was also larger in seven of the 
eight subjects when prazosin was given in combination. The 
elimination half life of prazosin was not changed by co­
administration of verapamil.
6.4. DISCUSSION
Only slight reductions in blood pressure were observed 
in these young normotensive subjects when verapamil was 
administered alone. This has been noted previously with 
other calcium antagonists (McAllister and Kirsten, 1982). 
Prazosin also had little effect on supine blood pressure but 
a significant orthostatic response was observed, confirming 
previous reports (Graham et al, 1977). The two drugs in 
combination produced a significantly greater hypotensive 
effect than either drug alone. There were greater falls in 
systolic and diastolic blood pressures, both supine and 
standing, and an earlier onset and longer duration of
147
subject 5
#--# prazosin + (verapamil) 
o—o prazosin
204
E
O)c
101
51z
COo
N
<cr
CL
#
21
0-5-
600400200 
TIME (mins)
Fig,6.5. Representative blood concentration-time 
profile for prazosin.
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action. This augmented effect of the combination appears to 
have been more than additive. In particular the reduction 
in supine diastolic pressure was larger than predictable 
from the summation of the individual drug effects.
There are a number of mechanisms, pharmacokinetic and 
pharmacodynamic, by which these drugs might interact to 
produce an augmented fall in blood pressure. In this study 
there was evidence of a pharmacokinetic interaction 
resulting in increased plasma concentrations of prazosin.
Both prazosin and verapamil undergo extensive first pass 
metabolism in the liver and both are highly protein-bound 
(Hamann et al, 1984; Keefe et al, 1981; Rubin and Blaschke, 
1980). If there had been simple competition by each drug 
for common metabolic pathways or for protein binding sites 
then changes in the kinetics of both drugs might have been 
anticipated. Differing affinities and specificities for these 
processes might explain why only prazosin’s pharmacokinetics 
were affected but there is no evidence to support this 
proposal.
Plasma concentrations of prazosin have previously 
been correlated with acute reductions in erect blood 
pressure (Bateman et al, 1979; Elliott et al, 1981) and it 
is likely that the increased plasma levels and 
bioavailability of prazosin contributed to the additional 
hypotensive effect of the combination. The explanation for 
the change in prazosin’s kinetics, but not those of 
verapamil, remains unclear but it may be related to acute
149
changes in liver blood flow.
In Chapter 4 of this thesis, according to other authors 
(Shand et al, 1981), the elimination of verapamil has been 
shown to occur more rapidly after acute dosing than after 
chronic administration. In addition, in this study 
verapamil, when administered alone, achieved peak plasma 
levels earlier than prazosin given alone. Verapamil may, 
therefore, have exerted its vasodilator effect also on the 
portal and splanchnic vascular bed at an earlier time. If 
it is hypothesised that liver blood flow is increased by 
verapamil the pharmacokinetics of verapamil itself might not 
be changed by the concomitant administration of prazosin, in 
view of its slightly delayed absorption, whereas the 
vasodilator effect of verapamil might influence prazosin’s 
kinetics causing a reduction in the extent of prazosin’s 
first pass metabolism as a result of a change in splanchnic 
blood flow, resulting in higher peak plasma concentrations 
and increased systemic bioavailability.
If the blood pressure reductions are analysed in terms 
of the differences in the areas of the blood pressure time 
curves then increases of 35 and 115% in the hypotensive 
effect are observed for standing systolic and diastolic 
pressures respectively, comparing prazosin alone and 
prazosin with verapamil. These percent changes in the 
areas of the blood pressure time curves seem to be 
consistent with the observed mean increase of 60% in AUC for 
prazosin when verapamil is concurrently administered.
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However, it seems disproportionate that this pharmacokinetic 
effect can entirely account for the 220% increase in 
hypotensive effect (as determined by the areas of the blood 
pressure-time curves) obtained for supine diastolic 
pressure. This suggests that there is an additional 
pharmacodynamic interaction.
It is possible that verapamil’s action to depress 
cardiac conduction produces an effect analogous to 
beta-adrenoceptor antagonism in attenuating the reflex 
increases in heart rate and cardiac output associated 
with prazosin. Thus, the hypotensive effect of prazosin is 
enhanced because the reflex cardiac responses are 
interrupted. In this study the greatest reductions in both 
supine and erect blood pressures caused by the verapamil- 
prazosin combination were associated with heart rates which 
were less than those obtained for prazosin alone. Only 
within the first 2 hours was there a transiently greater 
supine heart rate with the combination. This may simply 
have been due to the higher and more rapidly occurring peak 
plasma prazosin levels. Alternatively the cardiodepressant 
effects of verapamil may lag behind the vasodilator effects 
or may have a particular influence only when the heart rates 
show a more marked increase.
In conclusion, the combination of these two drugs may 
have acted at different sites enhancing the vasodilator 
effect by blocking alpha-j vasoconstrictor and impairing 
peripheral alpha2 mechanisms exciting a significantly
151
greater acute hypotensive effect than either drug alone.
152
CHAPTER 2
STUDIES ON THE EFFECTS OF CALCIUM ANTAGONIST DRUGS ON 
HEPATIC AND RENAL BLOOD FLOW
153
7.1. INTRODUCTION
The vasodilator properties of calcium antagonist drugs 
have been extensively investigated in several animal and in 
vitro studies particularly for the coronary arteries and the 
peripheral vasculature (Bou et al, 1983; Kazda et al,
1983). Although it is well established that the 
selectivity for different tissues and vascular beds varies 
with individual calcium antagonists, little information is 
available in man on the effects of this class of drugs on 
regional blood flow. It is only recently that increases in 
renal blood flow have been shown to occur after the acute 
intravenous administration the dihydropyridine calcium 
antagonists, nicardipine and nifedipine (Yokoyama &
Kaburagi, 198I and 1983). Similarly acute administration 
of nifedipine has been shown to increase apparent liver 
blood flow (Feely, 1984).
In the study on the interaction between verapamil and 
prazosin (Chapter 6), it was suggested that the augmented 
prazosin bioavailability might result from an acute increase 
in liver blood flow attributable to verapamil. However, 
there is evidence that verapamil not only modifies the 
pharmacokinetics of concurrently administered prazosin but 
that it also modifies its own pharmacokinetics. During 
chronic administration there are significant changes in the 
pharmacokinetics of verapamil, in comparison with the values 
observed after acute dosing, with prolongation of the 
elimination half-life and reduction of the clearance of the
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drug as observed in chapter 4 of this thesis and by other 
authors (Freedman et al, 1981; Kates et al, 1981; Shand et 
al, 1981), These changes have been generally ascribed to a 
reduction in hepatic clearance as a result of saturation of 
metabolic processes, with the resultant increase in systemic 
bioavailability and prolongation of elimination half-life 
(Kates et al, 1981; Shand et al, 1981) but there are no 
convincing data to support this hypothesis. While there is 
no good evidence that verapamil's pharmacokinetics deviate 
from first order metabolic processes there is evidence in 
another study (Woodcock et al, 1981) that the systemic 
clearance of verapamil is well correlated with apparent 
liver blood flow. Approximately 65% of the blood supply to 
the liver comes through the portal vein from the splanchnic 
bed and the gastro-intestinal tract, and since the liver is 
a crucial site for metabolic transformation of drugs its 
functional capacity might well be influenced by alterations 
to its blood supply (Dawson, 1979). Similarly, the kidney 
has a rich blood supply receiving 25% of total cardiac 
output and having a blood flow which is higher than any 
other parenchymatous organs and kept constant by the 
autoregulation (Shipley and Study, 1951; Bomzon, 1983). 
Recent studies have demonstrated that blood flow to the 
kidney may be altered by the acute administration of calcium 
antagonists (Yokoyama and Kaburagi, 1981 and 1983; Diamond 
et al, 1984; Ene et al, 1985).
This study was designed to investigate the effects on
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apparent liver and kidney blood flow and their possible 
relationships to pharmacokinetic changes following the acute 
and continued administration of two different calcium 
antagonists, verapamil and nisoldipine.
7.2. METHODS
Nine healthy normotensive male volunteers (aged 25 to
40 years; weight 52 to 76 kg) participated in the study.
The subjects were studied on five separate days after 
administration of
(1) placebo
(2) acute verapamil 160 mg and a further dose of
(3) verapamil 160 mg following three days of verapamil
treatment (80 mg b.d.)
(4) acute nisoldipine 20 mg and a further dose of
(5) nisoldipine 20 mg following 3 days of treatment 
(10 mg b.d.).
Active drugs and placebo were taken orally following 
an overnight fast. Subjects were not fed until 4 hours 
after dosing and rested supine throughout the study.
Placebo and active treatments were randomised and the 
treatment periods were at least one week apart. From an 
intravenous cannula inserted in a forearm vein blood 
samples were withdrawn at the following times: 0 and 15,
30, 45, 60, 90, 120, 150, 180, 240, 300, 360 and 480 minutes 
after dosing. Blood pressure and heart rate were measured 
by an automatic recorder (Sentron) at various times during
1 56
the study. Whole blood concentrations of verapamil and its 
metabolite, norverapamil, were determined by HPLC with 
fluorescence detection (Cole et al, I98I). The 
pharmacokinetic profiles of verapamil and norverapamil were 
most appropriately described by a model incorporating two 
compartments for drug disposition and a single compartment 
for the metabolite (see Figure 4.1.).
Parameter estimates were obtained by non linear least 
squares fitting using an "in house" program based on the 
Marquhardt algorithm (Bevington, 1969). Verapamil and 
norverapamil whole blood concentrations were simultaneously 
fitted to the following equations:-
C,,, = Ae-“ 'S> + - (A
(d )
C - Vc.klm A _ g-kmo(t^)
(m) Vm kmo - a
B
kmo - 3
(A + B) ^^-ka(t^) _ ^-kmo(t^) 
kmo - ka
(ti = t - t^ag
where A and B are coefficients, alpha and beta are the
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hybrid first order rate constants describing drug 
disposition, ka is the first order rate constant describing 
drug absorption, Vc.kim/Vm is a constant with Vc and Vm being 
the volume of central and metabolite compartments 
respectively, kmo is the first order rate constant 
describing metabolite elimination, and tlag is the time at 
which drug is first detected in the circulation.
Hepatic blood flow was assessed one hour after drug 
administration by the clearance of indocyanine green (ICG) 
as described in Chapter 2. ICG clearance in a 
representative subject is shown in Figure 7.1,.
Effective renal plasma flow and glomerular filtration 
rate were estimated by determining the clearance of 
hippuran and 51cr EDTA respectively as described in Chapter 
2. Effective renal plasma flow and glomerular filtration 
rate were calculated from the ratio of the amount of urinary 
excretion over 3 h and the area under the plasma 
concentration time curve, obtained using the trapezoidal 
rule, for ^^^I hippuran and *^^ Cr EDTA respectively (Harries 
et al., 1972). Subjects were also asked to collect urine 
until 24 hours after drug administration on each study day. 
Three separate collections were therefore taken, one between 
0 and 4 hours, another between 4 and 8 hours and from 8 to 
24 hours after either drug or placebo administration.
Student's paired 't' test with Bonferroni correction 
where appropriate, was used for all comparisons. Results 
are expressed throughout as mean + S.D.
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INDOCYANINE GREEN CLEARANCE
20J
SUBJECT 3
10-
5-
S
1 -
a.
placebo
0.2_ ^  verapamil chronic 
verapamil acute
Time (mln)
Fig. 7.1. ICG clearance changes in a representative 
subject.
159
7 . 3 .  RESULTS.
One subject experienced a minor allergic reaction after 
verapamil administration and therefore data are presented on 
eight subjects only.
Blood pressure and heart rate did not change 
significantly after either acute or chronic treatments as 
compared with placebo. The derived pharmacokinetic 
parameters following acute and chronic administration of 
verapamil are summarised in tables 7.1. and 7.2. and a 
representative pharmacokinetic profile (subject 3) is shown 
in Figure 7.2. Chronic administration was associated with a 
significant (p< 0.001) increase in area under the 
concentration time profiles (AUC) for both parent drug and 
metabolite. The mean drug AUC with acute administration 
was 800 + 353 ng.h/ml compared to 1455 ± 244 ng.h/ml for 
single dose administered following chronic treatment. The 
comparable figures for the norverapamil AUC were 731 ± 143 
ng.h/ml for acute administration and 1374 ± 365 ng.h/ml for 
chronic. The ratio of the verapamil and norverapamil AUC, 
a measure of the relative clearance of drug and metabolite, 
were not significantly different for acute and chronic 
administration. Verapamil terminal elimination half life 
(t1/2), and peak drug concentration (Cp) were both 
significantly (p<0.01) increased when chronic administration 
was compared with acute. However, absorption rate constant 
(ka) and time to attain the peak drug concentration (tmax) 
were not significantly changed by continued drug
160
31
CQ
<ï3
H
00 
E- 
UJjO 
0: LÜ 
HI ^  
CQ
cülz)
W  00
az oo| 
o|
SI< Ml 
LÜ
< | M
s:i 
2:|< 
OiCQ 
<CÜ
ii
Jj
M
o
° l ° 'sj ooj<H\ LÜ
wl cd 
H  SI Z) oj 
o
<<| w  
z
W M
OlH
•H
s
ro
CLi
CO
L
0)
>
o
C3
•H
s
CO
CL
CO
L
0)
>
L.
O
C
o
ZD
c
o
u
s:
o
s
CO
Cu
CO
S-
CD
>
L
O
C
o
=)
CO
C l
CO
CD
>
x:
o
X: (D 
. 4-5 
bO 3 
C  Ü
Ü
•H
c
o
c.
^  x:
M O
zr o o on Ln X— zr CM VO
tM CO «— zr r— o C\] CM (TV
o T— ir­ o T— r— T— 1— O
CD
4-3 cn vO T-- m o cn
3 LO T— z r in on o CTv o
O .
< o o O
Ü
•iH z r m VO CM CM CM CO z r
c CO VO H VO CO CO T— CM
o
u
z r crv LO VO z r z r VO
•=3-
m
cr>
VO
VO
o
CTV CD
=T
VO
VO
l>-
vO
O
IM CO
(\j
VO
CO
CO T—
o  +1 on
^  LTi 
H  +1 VO
on on
LT>
o
o
o
N/
CL
r—  on 
on +1 zf
O T- CM CO t— tM CM in z r
O o on m CO VO CO CO in +1 z r
O CM z r in CM z r CO on z r  CM
CM *— '=~
o
o
E-
O O
o
ZD
bO
C (D
LÜ M < w  4J CO o ov z r 0 - VO o o on
Lz, E- 3 crv c - in t— co CO o CO O  +1 LO
[z ,
Czl cc
O
<
in in in crv LO VO crv LO CO on
E—' WlZ 
n: ÜJ 
HlO 
S
0
01
4-5
o
CD
•f-iJD
3
00
on LO VO oo
+|oo
o
V
CL
161
we
<
H
M
CL,
<PC
LÜ
>
o |
t-4
s
O
CC
s
CJ|
Ql
S
Cl
SI
CJ 
w
"D
CQ 
Z )| CC\ 00| 
Ol
Wcol
OOIS
M
O  
M  
H  
<  
(Q  
H  
OQ 
0|M 
1 - 1  Z
H m
CxJlS 
s  Q  
M  <  
kd
o|
O
c
Z '
PC':
C :
Z |
0_
Q
W
>
M
OS
w
Q
I
O•iH
c
o
S-sz
X
CD SZ 
B  w
4-3
CÜ
Ü
•H
C
o
L
x:
o
CL bO <U
CM
4-5
CQ
O
•r4
c
o
L
x:
C_)
4-5
Ü
(D
■O
n
3
CO
zr crv CO o ro CO CM crv
1— o o t— 1— o T— O
+1
CM
40 X— crv CM VO zr CO T— m CM to
3 « • • • • « • • « +1 •
O 1— o 1— T— «— o X— 1— X— o
o o CO LO CO crv VO CM
VO z r VO CO z r CM crv VO
m CM CM r o CM t o V— CM
O  C  40 m CO CM LO OO LO CO zr
w  3 CM CO crv CTv c r, CM CO o
Ü CO X— X— CM X— X-
O  VO 
CO +1 LO 
CM
zr o
VO +1(0
o
o
o
V
CL
c VO z r CO H - o O CO CO 0
o • « • • . • • • +1 . 4_
L
X:
o
X:
0  \
1- 0
LO z r to CM to CM to
w
c
•H
1—1
Cm
r—1 
0
w  4_)
3
crv VO crv to !>- to LO crv z r  
+1 .
X:
O
<
CM CM CO CM CM CM c
o
0
4J
3 o LO o o CM o VO
Ü
< CO LO VO CM CO CO CO LO
CM CO * +1 .
lO  CM
O
V
CL
CM on LO VO CD
C  
CD 
<D
s: +|co
Q
c
o
•H
4J C 
CL O 
s.. -H
o +3
^  CD
c
(U
o
Ü
05
CL'
II
CO VO O X— crv VO crv o E
+1 . “H
VO VO b- CO crv LO CO LO 1 vO CM 1—1
4-5 40 
CD C  
c  CD
•H _p
W 
C  
O  
O
C
o
H
L
4-5 
C  
CD
It
O
0
CD ^  C 40 
•H  CD
S S- 
L  
0  40
ra
0
CL
o
40
0
I
CM
L
0 S
73 -H 
Ï- 40
O
II
r— 40
, to X
40 C. 0 
CQ "H E 
r—' 4-1 40
162
REPRESENTATIVE PHARMACOKINETIC PROFILE
500 _
Subject 3
acute300 _
chronic
200 _
cn
c
100 -I
50 -
CQ
03
B
120 _
108520
Time (h)
Fig. 7.2. Representative pharmacokinetic profile 
of verapamil following acute and 
chronic administration in a normotensive 
subject.
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administration.
7.3.1. Apparent Liver Blood Flow
Acute administration of verapamil was associated with 
significant (p < 0.005) increase to 1501 ± 363 ml/min 
compared to 945 ± 219 ml/min for placebo. With continued 
administration apparent liver blood flow was reduced to 1167 
± 375 ml/min (Figure 7.3.). Acute administration of 
nisoldipine was associated with a significant (p < 0.01) 
increase in apparent liver blood flow to 1310 ± 244 ml/min 
compared to placebo. Again, with continued administration 
apparent liver blood flow returned towards placebo values at
1154 + 216 ml/min (Figure 7.4,). There were no
significant changes in the volume of distribution of ICG 
with acute and continued administration of both drugs.
7.3.2. Renal blood flow
Effective renal plasma flow showed a similar pattern to
apparent liver blood flow with a significant (p < 0.001)
increase following acute administration of the two drugs (to 
628 + 140 ml/min for verapamil and to 624 ± 138 for 
nisoldipine compared to 507 ± 116 ml/min with placebo). 
Continued administration of the two drugs was associated 
with a reduction in renal plasma flow towards placebo values 
(Figures 7.5. and 7.6.). There were no significant 
differences in GFR after verapamil compared with placebo. 
Nisoldipine, however, increased GFR to 123 ± 14 ml/min after
164
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Fig.7.3. Apparent liver blood flow following verapamil administration 
in 8 subjects. Subject 3 is shown as O .
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Fig. 7.4. Apparent liver blood flow after acute nisoldipine (20 mg) 
and after 4 days of administration.(9 subjects).
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acute administration (p < 0.01 compared to placebo); with 
continued administration the GFR was back to placebo values.
The increase in GFR with acute administration of 
nisoldipine was paralleled by a modest increase in 24 hour 
urinary sodium excretion (218 ± 39 mmol compared to 201 ±  54 
mmol for placebo). This difference was significant when 
the Na"*" excretion within 4 hours of drug administration was 
considered (89 ± 41 mmol compared to 44 ± 27 mmol on placebo 
(p < 0.05) (Figure 7.7.). Total 24 hour urine volume was 1700 
±  500 ml after nisoldipine acute compared to 1380 ±  570 ml 
on placebo, the difference due to the significant increase 
in urine output obtaianed during the first 4 hours (653 ±
361 ml after nisoldipine compared to 337 ± 204 ml after 
placebo).
7.4. DISCUSSION
It has previously been reported (Kates et al, 1981;
Shand et al, 1981; Schwartz et al, 1982) that continued 
oral administration of verapamil is associated with a 
significant increase in area under the drug concentration 
time curve (AUC) and thus a decrease in clearance/F, These 
authors also reported increases in verapamil half-life 
following multiple dosing. Similar findings were observed 
in Chapter 4 but other studies, using deuterated verapamil, 
have failed to demonstrate this (Eichelbaum & Somogyi,
1984). The findings of the present study in normotensive 
males supports the observations that the decrease in drug
169
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Fig. 7. 7. Urinary sodium excretion after acute administration 
of nisoldipine 20 mg, verapamil 160 mg or placebo 
in normotensives.(n=9).
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clearance/F is also associated with significant but modest 
increases in elimination half life, A number of possible 
explanations of this phenomenon have been suggested. Of 
these the most widely held is the suggestion that the 
disposition of the drug following continued oral 
administration exhibits non-linear Michaelis-Menten 
kinetics associated with saturation of the first pass 
metabolic processes (Wagner, 1984). Verapamil is 
metabolised by several pathways to a number of identifiable 
metabolites including norverapamil (Eichelbaum et al, 1979) 
and in this present study, as well as in Chapter 4, no 
significant changes in formation or clearance of this 
particular metabolite (as reflected by similar values in the 
ratio of AUC drug to AUC metabolite for acute and chronic 
dosing) were demonstrated. Whilst this only provides 
evidence that this particular metabolic pathway is not 
saturated, it does suggest that other possible mechanisms 
should be considered. The changes in apparent liver blood 
flow observed in this study provide such a possible 
explanation, particularly as Woodcock et al (1981), have 
shown a good correlation between verapamil clearance and 
apparent hepatic blood flow. The differences in first dose 
and steady state pharmacokinetics may be accounted for by 
the observed pattern of the changes in liver blood flow 
particularly the profound increase in liver blood flow with 
acute administration and the subsequent return to baseline 
during continued drug administration. Indeed the kinetic
171
changes are not inconsistent with what would be anticipated 
by theoretical considerations of the changes in liver and 
splachnic blood flow (Wilkinson and Shand, 1975). However, 
it must be appreciated that blood flow determinations were 
made only on one occasion between 1 and 2 hours after 
dosing, whereas the kinetics were calculated over 8 hours. 
Thus it is not possible with these data to demonstrate a 
direct correlation and the hypothesis remains to be 
conclusively proved. A recently published study in 
patients (Schwartz et al, 1985) showed that ICG clearance 
was unchanged after repeated doses of verapamil. This was 
interpreted as evidence against the role of liver blood flow 
but unfortunately the acute effects of verapamil had not 
been assessed.
The changes in apparent liver blood flow with acute 
drug administration may also be relevant to the 
pharmacokinetic interaction between prazosin and verapamil 
described in a previous chapter. The co-administration of 
verapamil with prazosin gave rise to significantly higher 
peak plasma levels and increased systemic bioavailability 
for prazosin, whereas the pharmacokinetics of verapamil were 
not changed. It was noted that the peak plasma levels of 
verapamil were consistently achieved earlier than the peak 
prazosin levels. In the present study the profound changes 
in LBF with acute verapamil administration were measured 
almost coincidentally with the attainment of peak verapamil 
levels. Thus it is plausible to suggest that the increased
1 7 2
hepatic and splanchnic blood flow associated with acute 
verapamil administration was the main factor underlying the 
changes in prazosin disposition.
A number of factors including age, posture, exercise 
and food are known to alter apparent liver blood flow and 
thereby to affect the systemic clearance of drugs undergoing 
first pass metabolism (George, 1979). In these studies the 
subjects were young, healthy and investigated under 
controlled conditions so that changes in liver blood flow 
can reasonably be attributed to the administered drugs.
The renal circulation, however, is less susceptible to 
change and the glomerular filtration rate, in particular, is 
affected only by major haemodynamic disturbances. The 
efficiency of the renal autoregulation guarantees a steady 
blood supply which is relatively independent of the pressure 
within a range of 80-1 80 mmHg in the renal artery 
(Shipley and Study, 1951).
In the present study, in the absence of significant 
changes in blood pressure and heart rate, there were 
significant increases in effective renal plasma flow and 
glomerular filtration rate after acute administration of 
both drugs and a transient increase in urine output and Na"*" 
excretion after nisoldipine. Similar changes have been 
reported with other dihydropyridines (Leonetti et al, 1982; 
Ene et al, 1985). The mechanism by which calcium 
antagonist drugs cause a transitory alteration of renal 
autoregulation are not clearly understood. Similar
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findings have been reported in animals (Ono et al, 1974) and 
have been attributed to interference with prostaglandin 
secretion (Herbaczynska et al, 1973).
Alternatively alpha adrenoceptors mediating 
vasoconstriction have been identified on rat renal membranes 
(Pettinger et al, 1976; Schmitz et al, 1981) and the local 
vasodilator effect may result from interference by calcium 
antagonists on the adrenoceptor-mediated responses.
It is recognised that alterations in liver blood flow 
may significantly affect drug bioavailability and clearance 
(George, 1979; Daneshmend et al, 1981). It is thus 
important to consider potential pharmacokinetic interactions 
if calcium antagonist drugs are administered acutely with 
other drugs. The altered pharmacokinetics of prazosin 
demonstrate this type of interaction and the explanation may 
be the transient increased hepatic and splanchnic blood flow 
attributable to the calcium antagonist.
Whilst increased liver blood flow is an important 
determinant of the clearance of lipophilic drugs, it remains 
to be seen whether the corresponding increases in renal 
plasma flow and glomerular filtration rate will 
significantly affect the renal elimination of co­
administered polar drugs.
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CHAPTER 8
STUDIES ON THE EFFECTS OF CALCIUM ANTAGONISTS 
ON RELEASE OF HORMONES
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NICARDIPINE AND ANGIOTENSIN I I  MEDIATED ALDOSTERONE RELEASE
8.1. INTRODUCTION
Calcium ions were first proposed to be involved in the 
release of hormones, including catecholamines in 1963 
(Douglas & Rubin, 1963; Douglas and Posiner, 1964).
Several studies have since demonstrated that adrenal 
steroidogenesis is also calcium-dependent (Farese and 
Prudente, 1978) and that the aldosterone response to 
angiotensin II is associated with the intracellular 
accumulation of calcium ions (Shiraa et al, 1978; Fakunding 
& Catt, 1980; Foster et al, 1981). It has additionally 
been shown that the plasma concentrations of several peptide 
and steroid hormones, in response to physiological and 
pharmacological stimuli, are decreased by calcium antagonist 
drugs (Lin et al, 1979; de Marinis and Barbarino, 1980) but 
it is not yet clearly established in man that calcium 
antagonists have a clinically significant effect on hormone 
release in doses used in cardiovascular therapy.
For example, verapamil has been shown to inhibit the 
release of pituitary hormones (de Marinis and Barbarino, 
1980) whereas nifedipine has no effect on pituitary hormone 
release (Struthers et al, 1983) or on cortisol production 
(Millar et al, 1982). However, nifedipine has been shown to 
diminish the aldosterone response to angiotensin II (Millar 
et al, I98I; Vierhapper & Waldhausl, 1982). This 
inhibitory effect is not sustained during chronic therapy
176
(Bianchetti et al, 1982; Millar et al, 1983) although it 
has been observed that aldosterone levels are reduced, 
particularly in relation to the level of plasma renin 
activity (Thiebonnier et al, 1980; Hiramatsu et al, 1982).
Nicardipine hydrochloride is a new calcium antagonist 
under investigation for treatment of essential hypertension. 
It is a dihydropyridine analogue of nifedipine with similar 
activities on the heart and the peripheral vasculature but 
short duration of action (Taylor et al, 1982; Thuillez et
al, 1984; Van Schaik et al, 1984).
This study was designed to investigate the effects of 
acute and repeated dosing with nicardipine on the pressor, 
adosterone and other hormone responses to infused
angiotensin II in healthy normotensive males.
8.2. MATERIALS AMD METHODS
A random order double blind study was undertaken in six 
healthy normotensive sodium-replete males (23-26 years; 63- 
80 kg). To maintain the double blind design subjects were 
studied during three treatment phases, each of 1 week’s 
duration with oral medication (including matching placebo 
tablets) culminating in a final study day when intravenous 
therapy was added, including 0.9% sodium chloride solution 
as placebo. Three treatments were thus compared: (1) 
placebo (2) acute nicardipine by intravenous infusion (at 5 
mg/hour for 2.5 hours) (3) steady state nicardipine 
following 1 week of oral therapy with 30 mg t.i.d.
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On the final day of each treatment phase subjects 
reported to the Clinical Pharmacology Research Unit where 
they rested supine for 6 hours. An intravenous cannula was 
inserted into each forearm and a blood pressure cuff was 
attached. After not less than 20 minutes supine rest the 
intravenous infusion of nicardipine, 5 mg/hour, or an 
equivalent volume of 0.9% sodium chloride solution, was 
started to run for 2.5 hours. One hour later, via the 
cannula in the opposite arm, an intravenous infusion of 
angiotensin II was commenced to run for 1.5 hours with fixed 
incremental doses of 5, 10 and 20 ng/kg/min, each 
administered for 30 minutes.
Supine blood pressure and heart rate recordings, by 
semi-automated sphygmomanometer (Sentron) were made at 
frequent intervals, in particular at 5, 10, 20 and 30 minutes 
during each infusion dose. Venous blood samples were 
withdrawn at times 0, 1 hour (i.e. pre-angiotensin) and at
1.5, 2 and 2.5 hours (corresponding to the end of each of 
the three angiotensin dose levels) for subsequent 
measurement of plasma sodium and potassium, plasma renin 
activity, plasma noradrenaline, plasma angiotensin II, 
plasma cortisol and ACTH. Plasma nicardipine 
concentrations were assessed by HPLC with fluorescence 
detection.
8.2.1 . Statistical Analysis
Results throughout are expressed as mean ± SD and
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statistical evaluation was by repeated measures analysis of 
variance.
8.3. RESULTS
8.3.1. Blood pressure and heart rate
The supine and erect blood pressure and heart rate data 
following the first oral dose of 30 mg nicardipine are shown 
in Table 8.1. The only significant haemodynamic effect 
following the introduction of oral nicardipine was a 
transient increase in erect heart rate at 2 hours, 83 ± 11 
compared to 72 ± 12 bpm with placebo.
On the three study days there were no significant 
changes in supine blood pressure or heart rate associated 
with either acute intravenous administration or one week's 
therapy with oral nicardipine.
8.3.2. Pressor responses to angiotensin II
The mean blood pressure responses to the incremental 
infusion of angiotensin II are shown in Figure 8.1. The 
average increase in mean arterial pressure was significantly 
reduced by both intravenous and oral nicardipine (p < 0.05). 
Following 5 ng/kg/min the increase in mean arterial pressure 
was 9.1 ± 5.5 with placebo, compared to 4.7 ± 4.0 with 
intravenous and 4.8 ± 5.5 mmHg with oral nicardipine. The 
corresponding increases were 16.7 ± 7.6, 10.4 + 6.1 and 10.5 
+ 6.0 with 10 ng/kg/min and 23.6 ± 9.5, 13.4 + 6.7 and 16.5 
+ 7.3 mmHg with 20 ng/kg/min (Table 8.2.).
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TABLE 8 . 1 .
BLOOD PRESSURE AND HEART RATE FOLLOWING 10 mg. ORAL 
ADMINISTRATION OF NICARDIPINE IN 6 NORMAL SUBJECTS
MEAN + SD
PLACEBO NICARDIPINE
Supine Erect Supine Erect
Time 0 121/6? 121/76 116/66 122/73
(h)
± 4/4 ± 9/6 ± 7/5 ± 7/3
62 ±13 71 ±8 59 ±9 74 ±14
121/66 121/76 116/61 119/68
± 9/3 ± 9/6 ± 7/5 ± 10/7
59 ±10 72 ±12 63 ±8 83 ±11
122/61 124/72 117/59 118/73
± 10/4 ± 13/7 ± 9/8 ± 6/9
67 ± 8 81 ±10 66 ±10 82 ±13
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Fig.8.1. Angiotensin pressor responses.
Increase from baseline of mean arterial pressure. 
Mean from the measurements in 6 subjects at the 
given dose level.
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TABLE 8.2 .
PRESSOR RESPONSES TO MI INFUSIONS AFTER NICARDIPINE ADMINISTRATION
IN 6 NORMAL SUBJECTS
PLACEBO ORAL INTRAVENOUS
All 5 ng/kg/min 8.9 ± 5.5 5.2 ± 5.5 4.2 ± 4.0
10 16.5 ± 7.6 10.4 ± 6.0 10.4 + 6.1
20 20.9 ± 9.5 16.5 ±7.3 13.2 ± 6.7
Mean arterial blood pressure changes (mmHg)
Nicardipine (HCl (5 mg/h; 2.5 hrs) i.v. decreased significantly the
response to All infusion compared to placebo (paired t test: p < 
0.05).
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8.3.3. Aldosterone responses to angiotensin II
Plasma aldosterone concentrations are shown in Figure 
8.2. and Table 8.3. The baseline values after one week of 
oral nicardipine were not significantly different at 48 
± 20 compared to 44 + 13 pg/ml with placebo. In response 
to infused angiotensin there were wide inter-individual 
variations but there were no significant differences 
attributable to nicardipine in the patterns of response, 
with comparable increases in plasma aldosterone 
concentrations for all 3 treatments. At the highest dose 
of angiotensin infusion (20 ng/kg/min) the mean plasma 
aldosterone levels were 85 on placebo, compared to 73 with 
intravenous and 101 pg/ml with oral nicardipine.
8.3.4. Plasma Renin Activity
Plasma renin activity is summarised in Table 8.3.
There were no significant differences associated with oral 
or intravenous nicardipine, although with all three 
treatments plasma renin activity tended to fall during the 
angiotensin infusion.
8.3.5. Aldosterone ; renin ratio
On the placebo day, in response to the infusion of 
angiotensin II, there was a progressive increase in the 
aldosterone concentration/plasma renin activity ratio.
This increase was significantly attenuated by both 
nicardipine treatments (Figure 8.3.). At the highest
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TABLE 8.3.
PLASMA ALDOSTERONE AND RENIN ACTIVITY DURING All INFUSION 
FOLLOWING NICARDIPINE ADMINISTRATION IN 6 SUBJECTS
(MEAN ±  ^
BASELINE ANGIOTENSIN INFUSION
(ng/kg/min)
0 5 10 20
ALDOSTERONE
Normal range: 12-125 pg/ml
Placebo 43.6 
± 13.3
28.1 
± 10.8
64.3 
± 24.5
61.6 
± 16.6
84.5 
± 15.8
Intravenous
Nicardipine
50.6 
± 19.5
41.1 
± 9.2
50.1 
± 20.0
68.3 
± 20.4
73.3 
± 18.3
Oral
Nicardipine
47.5 
± 19.6
47
± 16.4
68.1 
± 18.4
87.8 
± 29.1
101.1 
± 23.9
RENIN ACTIVITY
Normal range: 4-12 ng Al/ml/hr
Placebo 1.2 1.0 0.5 0.3 0.4
± 0.8 ± 0.5 ± 0.3 + 0.1 ± 0.2
Intravenous 1.5 2.9 1.1 0.7 0.8
Nicardipine ± 1.0 + 1.8 ± 0.6 ± 0.4 ± 0.3
Oral 2.6 3.0 1.7 1.0 0.8
Nicardipine ± 1.5 ± 1.5 + 1.0 ± 0.5 + 0.4
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pg/ml
ALDOSTERONE RESPONSES TO ANGIOTENSIN II
1 2 0 -
Oral
Nicardipine2 100-
Placebo
Intravenous
Nicardipine
20-
1 20m*/k*/m*m
angiotensin II
0-^
VAr TT
1.0 1.5 2.0 2-6 time h
Fig.8.2. Mean plasma aldosterone concentrations before and 
during the angiotensin infusion at the given dose 
level in 6 subjects.
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Fig. 8.3 Aldosterone/renin ratios in response to infused 
angiotensin II at the given dose level in 6 
subjects.
1 8 6
level of infused angiotensin the ratios were 298 + 108, 172 
+ 112 and 108 + 26 on placebo, oral nicardipine and 
intravenous nicardipine respectively.
8.3.6. Plasma cortisol. ACTH and noradrenaline
These results are summarised in Table 8.4. Only the 
baseline (0 time) cortisol concentrations after 1 week of 
treatment with oral nicardipine were significantly different 
from the corresponding placebo values: 428 compared to 567
nMol/L. The associated ACTH also tended to be lower but 
this difference was not significant: 12.8 + 4.9 with oral
nicardipine, compared to 16.7 ± 10.9 for the intravenous day 
and 14.8 + 4.3 with placebo. Thereafter, during the time 
of the angiotensin infusion the plasma cortisol 
concentrations progressively declined but the responses were 
similar with all treatments. There were no significant 
differences for noradrenaline.
8.3.7. Plasma sodium and potassium
Plasma concentrations of sodium and potassium are shown 
in Table 8.5. There were no significant changes associated 
with administration of nicardipine either oral or 
intravenous compared to placebo during angiotensin II 
infusion.
8.3.8. Plasma nicardipine and angiotensin II concentrations
The nicardipine data were not adequate for individual
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TABLE 8 . 4 .
PLASI1A NORADRENALINE AND CORTISOL CONCENTRATIONS DURING All 
INFUSION FOLLOWING NICARDIPINE ADMINISTRATION IN 6 SUBJECTS
MEAN + SD
BASELINE
0
ANGIOTENSIN INFUSION 
ng/kg/min
5 10 20
NORADRENALINE
Normal range: 0-7 nMol/L
Placebo 1.6 1.9 1.4 1.4 1.7
± 0.4 ±0.6 ±0.5 ±0.7 ± 0.6
Intravenous 2.3 2.7 2.7 2.7 2.6
Nicardipine ± 1.3 ± 1.0 ± 1 .7 ± 1.2 ± 1.0
Oral 1.6 2.2 2.4 2.2 2.3
Nicardipine ± 0.3 ± 0.6 ± 0.5 ± 0.7 ± 1.5
CORTISOL
Normal range (0800): 330-770 nMol/L
Placebo 567 340 303 257 242
± 157 ± 98 ± 68 ± 65 ± 52
Intravenous 513 343 303 293 332
Nicardipine ± 137 ± 96 ± 99 ± 103 ± 135
Oral 428 345 332 302 308
Nicardipine ± 93 ± 78 ± 92 ± 105 ± 115
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analysis. The mean values following oral administration 
under steady state conditions and the mean concentrations 
during the acute intravenous infusion are shown in Figure
8.4.
The angiotensin levels showed wide interindividual 
variability but with the expected progressive increase 
during the infusion and with no significant differences 
during each study day.
8.3.9. General tolerance
Nicardipine was generally well tolerated. Mild 
headache was frequently reported during the first 24 hours 
of oral therapy but no subject had to interrupt the study on 
account of adverse effects.
8.4. DISCUSSION
There was no significant reduction in supine blood 
pressure, either with acute intravenous administration or 
during 1 week’s treatment with oral nicardipine in this 
group of young normotensives. A transient, slight increase 
in standing heart rate observed 2 hours after the first 
oral dose of 30 mg was the only evidence of a significant 
haemodynamic effect. These findings are consistent with 
previous observations in young normotensives (MacGregor et 
al, 1982; Millar et al, 1983) where only modest 
haemodynamic effects were seen after treatment with calcium 
antagonists.
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NICARDIPINE INFUSION 5 mg/hour
Plasma Nicardipine 
80 -I ng/ml
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Nicardipine 1 30mg orally 
30mg t.i.d. | 
f o r  1 week
r — r— 
0.5
 ____________20 ng/kg/min
-«10 ANGIÔTENSIN E
—T" 
1.0
—T—
1.5
—T— 
2.0
— I
2.5
Hours
Fig.8.4. Plasma concentration-time profiles for nicardipine 
following both intravenous and oral administration 
in 6 subjects.
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The intravenous administration of angiotensin II caused 
the expected dose-related increases in blood pressure (Bean 
et al, 1979). However, the pressor response to angiotensin 
was significantly and substantially attenuated by both 
intravenous and oral nicardipine, and although the expected 
increase in blood pressure was achieved in all subjects 
during placebo administration, the increases were very small 
in some subjects during nicardipine treatment. A similar 
reduction in pressor responsiveness to angiotensin has been 
reported for other calcium antagonists, including nifedipine 
(Millar et al, 1983), nisoldipine and verapamil (Chapter 5). 
There was no obvious relationship in individual subjects 
between the degree of antagonism of the pressor effect of 
angiotensin II and the plasma nicardipine concentrations 
but, for the whole group, attenuation of the pressor 
response tended to be greater with intravenous nicardipine 
and the highest plasma nicardipine concentrations were 
achieved following intravenous administration.
It has been suggested that inhibition of aldosterone 
production may be an important component of the 
antihypertensive effect of calcium antagonists (Millar et 
al, 1981) and there is evidence that nifedipine acutely 
inhibits the release of aldosterone (Millar et al, 1981; 
Vierhapper and Waldhausl, 1982). In this study the acute 
intravenous infusion of nicardipine did not significantly 
interfere with the magnitude of the aldosterone response. 
There is no conclusive evidence that long term therapy with
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nifedipine inhibits the aldosterone response (Bianchetti et 
al, 1982; Millar et al, 1983) and similarly one week’s 
therapy with nicardipine in this study had no significant 
effect. However, it has been observed that aldosterone 
levels are low relative to the level of plasma renin 
activity during chronic therapy with nifedipine (Thibonnier 
et al, I98O; Hiramatsu et al, 1982). In this study the 
aldosterone/renin ratio at baseline was not significantly 
altered by one week’s therapy with nicardipine. In 
response to infused angiotensin, however, there was some 
evidence of disturbance of the aldosterone/renin ratio, with 
significant reductions attributable to both nicardipine 
treatments. The clinical relevance of this remains 
unclear.
In conclusion this study has shown that nicardipine 
significantly attenuated the pressor responsiveness to the 
direct vasoconstrictor angiotensin, both acutely and after 
one week’s therapy. There was no significant effect on the 
aldosterone response to angiotensin II and no other evidence 
of clinically significant interference with hormone release.
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NIFEDIPINE AND INSULIN SECRETION IN HYPERTENSION
8.5. INTRODUCTION
Several studies using isolated perfused pancreas 
preparation (Grodsky & Bennett, I960) as well as islet-cell 
plasma membranes (Naber et al, 1980) have shown that calcium 
ions are involved in secretion of insulin (Wollheim and 
Sharp, 1981). It has been suggested that calcium 
antagonists might interfere with secretion of this hormone 
(Malaisse and Sever, I98I; Malaisse and Mathias, 1985).
There is also some evidence that the regulation of insulin 
secretion is under the alpha adrenoceptor mediated 
adrenergic control (Langer et al, 1983). Studies on 
peripheral vascular responsiveness (Chapter 5) indicate that 
effects mediated via alpha adrenoceptors may be affected by 
the administration of calcium antagonist drugs. Thus, 
either by a direct action on the secretory process, or by 
interference with the effector coupling process for 
adrenergic control mechanisms, calcium antagonists have the 
potential for reducing insulin release and disturbing 
glucose homeostasis.
There are a few studies in man which provide supportive 
evidence of impaired glucose tolerance attributable to 
calcium antagonists. Following an intravenous glucose load 
verapamil has been shown to decrease glucose tolerance (De 
Marinis et al, 1980) and a corresponding impairment of 
insulin response on oral glucose tolerance test has also
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been reported with nifedipine (Giugliano et al, 1980).
This study was designed to investigate the effect of 
acute and chronic administration of a slow release 
formulation of nifedipine on insulin secretion in a group 
of non diabetic patients with essential hypertension.
8.6. PATIENTS AND METHODS
Eight patients (5 M, 3 F; 58 + 6 years) with moderate 
essential hypertension gave their informed consent to take 
part in the study.
Patients were non-obese (Weight 70 ± 6 kg) and non­
diabetic and, on no previous treatment; blood pressure on 
two occasions was confirmed to be greater than 160/100.
Routine biochemical, clinical and EGG screening showed 
no evidence of concomitant diseases. After a two week 
period of placebo treatment patients attended the Clinical 
Research Unit where an intravenous glucose tolerance test 
(i.v. GTT 0.33 g glucose/kg body weight, as a bolus) was 
performed after an overnight fast. Blood samples for 
glucose (measured by standard glucose oxidase method) 
insulin and C-peptide (by radioimmunoassay) were collected 
via a cannula inserted in a forearm vein before and 5, 10, 20, 
30, 40, 50, 60 and 90 minutes after glucose administration.
The i.v. GTT was repeated on the first day (acute) and at 
the end of a 12 week period (chronic) with 20 mg twice daily 
nifedipine administered as the slow release formulation.
The test was performed two hours after either placebo
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or active treatment administration.
Patients attended the outpatient clinic at monthly 
intervals for blood pressure recording and review for 
possible side effects. Blood pressure and heart rate were 
measured twice in the sitting position by automatic recorder 
(SENTRON) before i.v. GTT. Throughout the period of trial 
patients were kept on a standardised well balanced 
normocaloric diet and were advised not to change their life 
style. Glucose, insulin and C-peptide responses to i.v.
GTT were calculated as incremental areas under the response­
time curve. Incremental area (I.A.) was the total area 
under the curve less the basal area (AUC = AUCt - AUCo).
The half time (t1/2) required for blood glucose to fall from 
a given level was determined and the K constant calculated 
from the formula K q  = 69.3 / t1/2 and expresses the 
percentage of blood sugar fall per minute (Seltzer, 1983).
Results are expressed as mean + SD and statistical 
evaluation was by analysis of variance; differences were 
considered significant when p < 0.05.
8.7. RESULTS
The baseline (pre-i.v. GTT) measurements of glucose, 
insulin and C-peptide were not significantly different 
during nifedipine treatment. Blood glucose was 5.2 mmol/L on 
placebo, 5.1 on the acute day and 5.2 on the chronic day. 
Insulin and C-peptide concentrations were 9.1 and 0.97 
respectively on the placebo day, 10.4 and 0.81 on the acute;
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10.9 jLiU/ml and 0.97 nmol/ml after 12 week treatment (Table 
8.6.).
Incremental areas under the response-time curve for 
glucose were 4920 + 1060 on placebo, 4890 + 1290 on 
nifedipine acute and 4240 ± 950 mg/ml min after 12 weeks. 
Incremental areas for insulin were 2190 + 490 on placebo, 
1910 + 470 on the first and 21 60 + 620 ^U/ml min on the last 
day of treatment. Incremental areas for C-peptide were 
78.5 ± 16 on placebo, 76.3 ± 8 after acute and 72.1 + 12 
nmol/ml min after chronic administration of nifedipine 20 mg 
as monotherapy (Table 8.7. Figure 8.5.). Kq. was 1.78 ±
0.3 (range 1.5 ± 2.2) at baseline, 1.59 ± 0.4 on the acute 
and 1.69 ± 0.3 on the chronic day.
Both acute and chronic treatment with nifedipine caused 
significant reduction of blood pressure (BP). BP sitting 
was 175/1 04 + 9/5 on the placebo day and fell to 1 53/92 +
9/5 after administration of the first dose of nifedipine; 
on the chronic day BP was 153/90 + 8/6 mmHg (p < 0.01 
compared to placebo). Corresponding heart rates were 74 ±
9 on the placebo day, 79 ± 10 on the acute day and 75 ± 8 
b/min after 12 week therapy (Figure 8.6.).
8.8. DISCUSSION
Although there are reports of impaired glucose 
tolerance with both verapamil and nifedipine there are a 
number of other studies which have shown no significant 
effects of calcium antagonists on glucose tolerance or
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TABLE 8.6 .
BASELINE METABOLIC PARAMETERS FOLLOWING NIFEDIPINE (20mg) 
ADMINISTRATION IN 8 HYPERTENSIVE PATIENTS 
(MEAN + SDl
PLACEBO NIFEDIPINE NIFEDIPINE 
ACUTE CHRONIC
Glucose 5.2 ± 0.4 5.1 ± 0.6 5.2 ± 0.5
(mmol/L)
Insulin 9.1 ± 4 10.4 + 7 10.6 + 6
(jnU/ml)
C-peptide 0.97± 0.4 0.81+ 0.4 0.97 ±0.4
(nmol/ml)
N.S.
N.S.
N.S.
1 98
TABLE 8.7.
INCREMENTAL AREAS FOR GLUCOSE. INSULIN AT® 
C-PEPTIDE FOLLOWING NIFEDIPINE (20mg) ADMINISTRATION 
IN 8 HYPERTENSIVE PATIENTS 
(MEAN + m i
PLACEBO NIFEDIPINE NIFEDIPINE
ACUTE CHRONIC
Glucose 4920 ± 1060 4890 ± 1290 4240 ± 950 N.S.
(mg/ml min)
Insulin 2190 ± 490 1910 ± 470 2160 ± 620 N.S.
(juU/ml min)
C-peptide 78.5 ± 16 76.3 ± 8 72.1 ± 12 N.S.
(nmol/ml min)
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Fig.8.5. A schematic representation of the evaluation 
of incremental area (lA) = total area - basal 
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insulin secretion. Whereas verapamil administered 
intravenously seemed to impair glucose tolerance and to 
reduce insulin secretion in patients with islet-cell tumor 
(De Marinis, I98O) chronic oral administration had no 
significant effects in a group of patients with angina 
pectoris (Semple et al, 1983).
In contrast, nifedipine 10 mg three times daily for 
ten days, impaired insulin secretion but improved glucose 
tolerance in a group of non-diabetics (Giugliano et al, 
1980), In addition, nifedipine 20 mg t.i.d, has been 
associated with hyperglycaemic effect as assessed by oral 
glucose tolerance testing, in a group of normal subjects 
(Charles et al, 1981) and with the development and 
deterioration of diabetes mellitus in hypertensive patients 
(Bhatnagar et al, 1984). In view of these conflicting 
reports about the effect of calcium antagonists on 
glucose/insulin regulation the principal aim of this study 
was to establish, using i.v. GTT whether or not nifedipine 
in its most widely used slow release formultion had any 
significant effect on insulin secretion in a group of 
hypertensive patients. In this study an i.v. GTT was 
performed in a group of non-diabetics after acute and 
chronic administration of nifedipine monotherapy.
Calculated incremental areas for glucose, C-peptide and 
insulin did not show significant differences for nifedipine 
compared to placebo, indicating that the drug did not impair 
insulin secretion. Perhaps a balance of subtle inhibition
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in secretory process with a subtle inhibition of the alpha2 
adrenergic effect, which is itself inhibitory, has occurred 
leading to unchanged secretion (Nakaki et al, 19&0; Langer 
et al, 1983). Moreover, Kq which is an index of glucose 
removal rate was not significantly altered by the drug.
These data are consistent with lack of effect on other 
hormone release after repeated dosing of nifedipine (Millar 
et al, 1983).
In conclusion this study indicates that nifedipine as 
standard antihypertensive therapy does not impair insulin 
release or glucose tolerance in response to an intravenous 
glucose load.
203
CHAPTER a
GENERAL DISCUSSION
204
GENERAL DISCUSSION
The principal aim of the research described in this 
thesis was to investigate aspects of the clinical 
pharmacology of calcium antagonist drugs in both normal 
subjects and in hypertensive patients. Most of the studies 
have involved the established calcium antagonist drugs, 
nifedipine and verapamil, but other newer dihydropyridines, 
nicardipine and nisoldipine, have also been studied. The 
inclusion of these newer compounds is a reflection not only 
of the considerable, recent increase in the number of drugs 
acting upon slow calcium channels, but also of the increased 
awareness of the central role of calcium in a variety of 
intracellular processes.
In contrast with other antihypertensive drugs, the 
calcium antagonists produce little or no change in the blood 
pressure of normotensive subjects. This has been reported 
by a number of other observers (Leonetti et al, 1982;
Hulthen et al, 1982; MacGregor et al, 1983; Millar et al,
1983) and was confirmed in the first study described in 
which the effects of the new dihydropyridine, nisoldipine, 
were compared with nifedipine in normal volunteers and then 
assessed in hypertensive subjects (Chapter 3). Based on 
this difference in responsiveness it has been proposed that 
increased intracellular ionised calcium in vascular smooth 
muscle is the final determinant of the increased peripheral 
vascular resistance observed in essential hypertension 
(Jones, 1974; Orlov and Postnov, 1982). Therefore, the
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hypothesis has been developed that calcium antagonist drugs 
are particularly appropriate for "correction" of this 
abnormality (Buhler, 1983). Using the platelet as a model 
for the vascular endothelial cell, support for this 
hypothesis has been derived from the observed relationship 
between an increased Ca++ content in the platelets of 
hypertensive patients and the subsequent "normalisation" of 
this content with antihypertensive treatment (Erne et al,
1984). However, other groups studying leucocytes have 
shown that calcium-sodium exchange is not corrected by 
nifedipine (Haegerty, 1983).
The response to calcium antagonists is not determined 
solely by an elevated blood pressure and other 
pathophysiological factors, such as age, sodium intake, 
plasma renin activity and circulating catecholamines, must 
be taken into account in the interpretation of the 
antihypertensive effect. For example, a direct correlation 
between age and blood pressure response has been 
demonstrated by some authors (Buhler, 1982) and this has 
further been related to the renin-angiotensin system whose 
activity decreases with age (Hulthen et al, 1982).
However, the inter-relationship between age, blood pressure 
response and plasma renin activity has been disputed in both 
clinical studies (Ferrara et al, 1985) and animal studies 
(Waeber et al, 1985).
Sodium intake not only affects the activity of the 
renin-angiotensin system (Brown et al, 1963) but also
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affects cardiovascular responses to adrenergic stimulation 
and circulating catecholamines (Fraser et al, 1981) and 
plasma noradrenaline tends to rise with age (Ziegler et al, 
1976). In addition, calcium antagonist drugs themselves 
have been shown to acutely increase plasma renin activity 
(MacGregor, 1982) although this increase is not sustained 
during chronic treatment (Lederballe et al, 1980; Kiowski 
et al, 1983a). Similarly an acute increase in circulating 
catecholamines occurs, particularly with nifedipine (Murphy 
et al, 1982) as a consequence of a baroreflex-mediated 
release that also determines a transitory increase in heart 
rate (Lederballe et al, 1979; Littler, 1983).
Another point of uncertainty was whether or not blood 
pressure reduction was related to the plasma concentration 
of calcium antagonist drug, particularly verapamil that has 
shown changing kinetics with continued administration 
(Freedman et al, 1981; Shand et al, I98I). Applying 
concentration effect analysis to the data collected (Chapter 
4) the results suggested that the differences in 
responsiveness observed might be due to change in 
pharmacokinetics .
In the individual patient, therefore, there are several 
factors which affect the response to a calcium antagonist 
drug and the precise mechanism of the antihypertensive 
action of this type of drug is still subject to discussion. 
Considering the heterogeneity of the factors involved in the 
pathophysiology of essential hypertension and the various
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factors which can influence the blood pressure response to 
treatment with calcium antagonists, the interactions of 
these drugs with other systems, including the adrenergic 
nervous system were investigated in more detail.
Sympathomimetic amines promote calcium entry and 
potentiate contraction. Calcium antagonists, on the other 
hand, affect alpha adrenoceptor function as demonstrated in 
vitro and in animal studies (Karliner et al, 1982;
Pedrinelli and Tarazi, 1984). Several in vitro studies and 
animal studies have convincing data supporting the 
hypothesis that either alpha^ or alphag adrenoceptors 
modulate the entry of extracellular calcium in vascular 
smooth muscle (Vanhoutte, 1982b; Vanhoutte and Rimele,
1982; Van Zwieten et al, 1982). Human studies have also 
clarified the postjunctional role of alpha2 adrenoceptors in 
the vasoconstriction of arteries (Elliott et al, 1983; 
Kiowski et al, 1983; Murphy et al, 1984a).
Some authors had proposed that calcium antagonists 
selectively inhibit alpha2 adrenoceptor responses (Motulsky, 
1982). The data shown in Chapter 5 demonstrate that 
calcium antagonists impair pressor responses to 
phenylephrine as well as alpha-methylnoradrenaline 
showing, therefore, an interference with both alpha^ and 
alpha2 mediated pressor response. Furthermore, the pressor 
response to angiotensin II was inhibited suggesting a non- 
selective interaction with alpha adrenoceptors and non 
adrenergic mechanisms.
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To further investigate the proposed interference of 
calcium antagonists with alphag receptors, a study on 
platelets was undertaken. Platelets represent a very 
interesting model to study the alphag receptor (Erne et al, 
1983; 1985). Several analogies link vascular smooth muscle 
cell to platelets, and these cells can be used as a model in 
both cardiovascular research and the study of 
pathophysiological processes in hypertension. Furthermore, 
platelets play a key role in thrombosis and in the 
progression of atherosclerosis. If an antiplatelet action 
of calcium antagonists could be shown in long term clinical 
studies, this could be of importance in the prevention of 
ischaemic diseases. In the platelet study both verapamil 
and nisoldipine inhibited adrenaline induced platelet 
aggregation in vitro confirming an interaction with the 
alpha adrenergic system.
In view of these observations on the relationship 
between alpha adrenergic mechanisms and calcium channels 
another study was undertaken on the use of the alpha 
blocker, prazosin, together with the calcium antagonist, 
verapamil (Chapter 6). An enhanced hypotensive effect was 
achieved using the two drugs in normotensives which seemed 
to result from both a dynamic and a kinetic interaction.
The increased bioavailability of prazosin could be 
responsible for the larger fall in blood pressure observed 
as, according to other authors, prazosin blood levels are 
related to response (Bateman et al, 1979; Larochelle et al.
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1982), An additional dynamic factor, however, contributed 
to the interaction causing a significant reduction in supine 
diastolic blood pressure. Total peripheral resistance may 
have been significantly reduced by affecting simultaneously 
alpha-j adrenoceptors and calcium channels in the arterioles.
An effect similar to that described for beta blockers 
(Elliott et al, 1981) was also observed with verapamil that 
attenuated the reflex tachycardia due to prazosin. It is
also conceivable that verapamil slightly depressed 
atrioventricular conduction. The results of this study 
open the possibility to further investigate the combination 
in the treatment of hypertension.
In the study of the interaction between verapamil and 
prazosin, it was suggested that the observed prazosin 
pharmacokinetics resulted from a change in the hepatic 
extraction of prazosin, reflecting an increase in liver or 
splanchnic blood flow due to the calcium antagonist. To 
further investigate the effects of calcium antagonist drugs on 
liver and kidney blood flow a comparative study was 
undertaken with verapamil and nisoldipine (Chapter 7). The 
liver has a system of blood flow autoregulation called the 
hepatic arterial buffer response. Portal venous blood flow 
is the major regulatory factor within this system whereby 
total hepatic blood flow is maintained at a constant level 
through compensatory alterations to hepatic arterial flow 
(Lautt, 1985). An increase of apparent liver blood flow, 
as measured by the clearance of indocyanine green, was
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demonstrated following the first dose of either nisoldipine 
or verapamil. This finding was observed within the first 2
hours of drug administration suggesting a transitory
alteration of hepatic blood flow autoregulation. A 
consequence of this alteration to apparent liver blood flow 
could be changes in the hepatic clearance of drugs co­
administered with the calcium antagonist (c.f. prazosin) but 
this requires further detailed evaluation.
Of additional interest are the findings of acute changes 
in blood flow and glomerular filtration rate of the kidney 
which again suggest a transitory impairment of renal 
autoregulation secondary to the vasodilator influence of the 
calcium antagonists. With nisoldipine there was also 
evidence of an effect on the function of the nephron with an
increase in sodium excretion within a few hours of
administration. To account for this natriuretic effect an 
interference by the dihydropyridines on the adrenergic 
receptor affecting sodium reabsorption in the tubule has been 
postulated (Leonetti et al, 1982; Zanchetti, 1985). The 
different effect on sodium excretion and urine output may 
reflect a different affinity of the two drugs for the afferent 
and the efferent arterioles. An alternative, or 
additional, factor in increased natriuresis observed with 
nisoldipine may be inhibition of the effect of aldosterone 
on the tubule but there is no evidence to support this 
hypothesis.
Another subject of investigation of this thesis was
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the potential interference by calcium antagonists, 
particularly dihydropyridines, of the calcium-dependent 
release of hormones (Chapter 8). Previous observations had 
shown that nifedipine acutely inhibited the aldosterone 
response to exogenous angiotensin II (Millar et al, 1981) and 
a corresponding study was undertaken with nicardipine. In 
contrast to the findings with nifedipine, nicardipine did not 
affect significantly the magnitude of the aldosterone response 
to angiotensin II infusion in normal volunteers, although a 
similar attenuation of the blood pressure response was 
observed. A possible explanation for this difference is that 
nicardipine has lesser affinity for the adrenal cortex than 
nifedipine, but whether or not this mechanism has an important 
role in the reduction of blood pressure remains to be 
established.
Hormonal and metabolic aspects were further investigated 
in a group of hypertensive patients. A number of studies 
have reported deterioration of blood glucose control in diabetic 
patients taking nifedipine for treatment of concomitant 
hypertension (Giugliano et al, 1980; Bhatnagar et al, 1984).
In addition to glucose intolerance, antihypertensive drugs, 
particularly thiazide diuretics, are known to adversely affect 
other metabolic risk factors, such as increased plasma 
lipids and augmented uric acid (Ames and Hill, 1976;
Weidmann et al, 1985). In the study undertaken with 
nifedipine no significant impairment of insulin secretion or 
glucose tolerance after acute and chronic administration was
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observed. The lack of side effects of this kind, if 
confirmed with longer term studies, could be an advantage to 
consider in the choice of the drug for treatment of 
hypertension.
Other points must be taken into account. Calcium 
antagonists are vasodilator drugs but, among them, verapamil 
does not cause reflex tachycardia nor increase renin 
secretion (Muiesan et al, 1982). As a class they do not 
induce fluid or sodium retention and some of them have, at 
least at the beginning of therapy, a natriuretic and a 
diuretic effect (Leonetti et al, 1980). These drugs seem 
to be as effective as beta blockers in the control of high 
blood pressure and are also devoid of the contraindications 
that apply to beta blockers, such as asthma or heart 
failure. Furthermore a possible "cardioprotective" role of 
these drugs may be suggested considering the favourable use 
in treatment of angina pectoris. This aspect also requires 
long term clinical investigations.
These considerations are of important clinical relevance 
because they may suggest the use of calcium antagonists as a 
first line drug as well as beta blockers and diuretics.
When the blood pressure is inadequately controlled, a 
rational next step is the addition of a beta blocking agent 
(Buhler, 1983) since the cardiac and the renin-angiotensin 
mediated counter-regulatory mechanisms induced particularly 
by nifedipine can, in principle, be antagonised by beta 
blockers. In contrast to verapamil, a depressant effect on
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cardiac pacemaker cells and prolongation of the AV 
conduction is not likely to occur with the combination of 
nifedipine and beta blocker, since nifedipine has fewer 
direct cardiac effects (Singh et al, 1982). The 
combination of a calcium antagonist with a diuretic or a 
converting enzyme inhibitor could theoretically also be 
effective. However, at present clinical experience with 
these combinations is limited.
The calcium antagonists certainly represent a fascinating 
group of drugs whose various properties may prove to be of 
great value in the treatment of a variety of clinical 
conditions in the future.
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